Entries |
Document | Title | Date |
20080206130 | IN VIVO PANNING FOR LIGANDS TO RADIATION-INDUCED MOLECULES - A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. The method includes the steps of: (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are therapeutic and diagnostic methods using targeting ligands that bind an irradiated tumor. | 08-28-2008 |
20080213165 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods - The present application discloses methods and compositions for increasing patient tolerability during myocardial imaging comprising the administration of doses of caffeine and one or more adenosine A | 09-04-2008 |
20080253960 | Lipoprotein-Based Nanoplatforms - The present invention provides a non-naturally occurring lipoprotein nanoplatform (“LBNP”) comprising at least one cell surface receptor ligand; at least one lipoprotein; and at least one diagnostic agent and/or at least one therapeutic agent. In embodiments of the present invention, the cell surface receptor ligand is not a low-density lipoprotein receptor ligand and the cell surface receptor ligand is covalently bonded to the apoprotein. The present invention also provides pharmaceutical formulations comprising LBNPs and methods of making the LBNPs. | 10-16-2008 |
20080253961 | Formulation of Active Agent Loaded Activated PLGA Nanoparticles for Targeted Cancer Nano-Therapeutics - The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and places the targeting agent on the exterior surface of a biodegradable nanoshell, wherein an active agent is loaded with the nanoshell. | 10-16-2008 |
20080267861 | Myocardial Perfusion Imaging - This invention relates to methods for performing myocardial perfusion imaging for diagnosing and characterizing coronary artery disease using an intravenous (IV) bolus injection of regadenoson while the patient is undergoing sub-maximal exercise. | 10-30-2008 |
20080267862 | METHOD OF TREATING CANCER - Present invention provides a method for treating cancer which comprises co-administration of an angiogenic agent to enhance the vascular supply within tumors, particularly tumors capable of maintaining their viability under hypoxic conditions, and a anticancer therapy (e.g. chemotherapy and radiation therapy) to which the cancer is susceptible. Induction of angiogenesis increases the delivery of anticancer agents to the hypoxic tumor cells within the tumors, and as a result, improves the effectiveness of the anticancer therapy in eliminating or reducing cancers. The present invention also includes formulations comprising of lysine(L- and/or D-isomers as well as, or, their “activated” version either in isolation or in various combinations, as described, along with additive(s) and one or more chemotherapeutic agent(s) and/or radio-sensitizing agent(s). | 10-30-2008 |
20080279764 | METHOD AND COMPOSITION FOR TREATING CANCER - A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or a human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species. | 11-13-2008 |
20080279765 | Novel Imaging Agents for Fibrosis - The present invention provides a novel imaging agent targeting the mannose-6-phosphate (M6P) receptor suitable for the non-invasive visualization of fibrosis. A method for the preparation of the imaging agent is also provided by the invention, as well as a precursor for use in said method. The invention also provides a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical composition. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition in which the mannose-6-phosphate receptor is upregulated is provided. | 11-13-2008 |
20080292544 | Modified Proteins, Designer Toxins, and Methods of Making Thereof - The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositions have significant benefits to a subject in need of such compounds and compositions. Also included are modified toxin compounds that are truncated and/or possess reduce antigenicity. Such designer toxins have therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins. Methods of treating cancer using these immunotoxins are provided. | 11-27-2008 |
20080317666 | Colonic Delivery of Active Agents - Drug delivery devices that are orally administered, and that release active ingredients in the colon, are disclosed. In one embodiment, the active ingredients are those that inactivate antibiotics, such as macrolides, quinolones and beta-lactam containing antibiotics. One example of a suitable active agent is an enzyme such as beta-lactamases. In another embodiment, the active agents are those that specifically treat colonic disorders, such as Chrohn's Disease, irritable bowel syndrome, ulcerative colitis, colorectal cancer or constipation. The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethyleneimine. The high crosslink density of the polyethyleneimine is believed to stabilize the pectin beads for a sufficient amount of time such that a substantial amount of the active ingredients can be administered directly to the colon. Advantageously, the amount of polyethyleneimine is sufficient to allow a substantial portion of the pectin beads to pass through the gastrointestinal tract to the colon without releasing the active agent, and is also sufficient such that the pectin beads are sufficiently degraded in the colon to release an effective amount of the active agent. | 12-25-2008 |
20090004101 | Method and Means for Enhanced Pulmonary Drug Delivery - The present invention provides a method of enhancing the absorption of molecules across the airway epithelium, thereby enhancing the delivery of desired therapeutic or diagnostic agents across the airway epithelium via the systemic circulation to the target site of action. The method comprises administration of a formulation comprising a pharmaceutical composition comprising a synthetic or natural nucleoside diphosphate, nucleoside triphosphate, or dinucleoside polyphosphate, together with a pharmaceutically acceptable carrier. Preferably the nucleotide is a P2Y receptor agonist which is administered at any time during treatment with a therapeutic or diagnostic agent. A preferred embodiment is a method of administering a pharmaceutical composition comprising a P2Y receptor agonist with enhanced resistance to extracellular hydrolysis, such as dinucleoside polyphosphate compounds. | 01-01-2009 |
20090004102 | HSC70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease - Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a heat shock cognate (HSC70) protein 70 on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the HSC70 protein on the surface of a normal cell. | 01-01-2009 |
20090010838 | Pyridylacetylenes for Use as Radiotracers and Imaging Agents - The present invention relates to novel pyridylacetylene derivatives of formula I | 01-08-2009 |
20090010839 | Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy - Dimers of avidin and streptavidins (diavidins) are described wherein the linker is suberate, which in turn, is bound to different functional groups (—NH2 o-COOH) of avidin. As compared to avidin, the diavidins have shown the ability to increase the amount of labelled biotin on the target, when used in an in vitro pretargeting test using supported human tenascin, the biotinylated anti-tenascin monoclonal antibody (Mab-B), avidin/diavidin, and biotin- | 01-08-2009 |
20090028784 | Antibodies to IL-6 and use thereof - The present invention is directed to antibodies and fragments thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 01-29-2009 |
20090028785 | MEDICAL DEVICES WITH COATINGS FOR DELIVERY OF A THERAPEUTIC AGENT - Described herein are implantable coated medical devices, such as intravascular stents, for delivering therapeutic agents to the body tissue of a patient, and methods for making such medical devices. In particular, described herein are implantable coated medical devices comprising a substrate having a surface, and a coating disposed upon the surface that comprises a coating composition that includes a releasable metal oxide. The coating is free of polymer or a particular type of polymer that is not a part of any releasable metal oxide. | 01-29-2009 |
20090028786 | METHODS AND APPARATUS FOR IMAGING AGENTS FOR DISEASE DETECTION - Methods and apparatus for identifying disease status according to various aspects of the present invention include delivering one or more imaging agents to all or parts of the body for disease observation, screening and/or detection. The methods and apparatus may deliver imaging agents that include any suitable disease-associated compositions, such as riboflavin carrier protein (RCP) and/or RCP modifications and antibodies thereof, labeled with an imaging label. In one embodiment, the imaging agents may be delivered to a selected site or sites in the body and subsequently observed using an imaging method. In another embodiment, the imaging agents may be delivered throughout the body for screening applications. In yet another embodiment, the imaging agents may be delivered throughout the body to detect a reduction and/or increase in cellular metabolism. | 01-29-2009 |
20090047209 | Novel nifedipine compositions - The present invention is directed to nanoparticulate compositions comprising nifedipine. The nifedipine particles of the composition have an effective average particle size of less than about 2 microns. | 02-19-2009 |
20090047210 | Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1 - MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis. | 02-19-2009 |
20090074657 | Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof - The present invention is directed to monoclonal, chimeric or humanized, antibodies or antibody-like molecules that recognize an epitope common to human acidic and basic isoferritins. The anti-ferritin antibodies or antibody-like molecules can be used in pharmaceutical compositions for immunotherapy or radioimmunotherapy to target various cancer cells in a mammal. A method for delivering anti-ferritin antibodies or antibody-like molecules to cancerous lymph cells, pancreatic cells, lymphatic endothelium cells, and liver cells is also disclosed, as well as methods for treating pancreatic cancer, hepatocellular carcinomas, Kaposi's sarcoma and Hodgkin's lymphoma. | 03-19-2009 |
20090074658 | COMPOSITIONS AND METHODS FOR GENERATING AND SCREENING ADENOVIRAL LIBRARIES - The present invention provides DNA libraries, libraries of viral clones and libraries of infectious viral particles and methods of generating and screening these libraries. | 03-19-2009 |
20090081119 | INHIBITING DNA POLYMERASE BETA TO ENHANCE EFFICACY OF ANTICANCER AGENTS - The invention provides anticancer methods. In one embodiment, the inventive method involves the co-administration to cancerous cells of (a) a chemotherapeutic agent, radiation, or a combination of a chemotherapeutic agent and radiation and (b) an inhibitor of DNA polymerase beta. In another embodiment, the invention provides anticancer methods involving the co-administration to cancerous cells of (a) a chemotherapeutic agent, radiation, or a combination of a chemotherapeutic agent and radiation and (b) an siRNA or shRNA in an amount sufficient to attenuate base excision repair within the cell. Another aspect of the invention relates to pharmaceutical compositions comprising an siRNA or shRNA that attenuates base excision repair. | 03-26-2009 |
20090081120 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods - The present application discloses methods and compositions for increasing patient tolerability during myocardial imaging comprising the administration of doses of caffeine and one or more adenosine A | 03-26-2009 |
20090104113 | Ionizing-radiation-responsive compositions, methods, and systems - A method, composition and system respond to ionizing, radiation to adjust biological activity. In some approaches the ionizing radiation is X-ray or extreme ultraviolet radiation that produces luminescent responses that induce biologically active responses. | 04-23-2009 |
20090104114 | Nanotherapeutic Colloidal Metal Compositions and Methods - The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, the nanotherapeutic compositions of the present invention comprise a platform comprising a colloidal metal, a targeting ligand such a tumor necrosis factor, a stealth agent such as polyethylene glycol, and one or more diagnostic or therapeutic agents for delivery. The invention also comprises methods and compositions for making such nanotherapeutic compositions and for the treatment of cancer. | 04-23-2009 |
20090110632 | BIOLOGICAL MATERIALS AND USES THEREOF - There is provided by the invention a modified antibody molecule which selectively binds to a specific target, the antibody molecule being modified at, at least one amino acid residue that forms part of a glycosylation site in the variable region of an unmodified parent antibody molecule, characterised in that the modified antibody is not glycosylated at the previous glycosylation site of which the amino acid modification forms part and the modified antibody exhibits a greater binding affinity for the specific target than the unmodified parent antibody molecule. There is also provided nucleotide sequences, amino acid sequences and expression vectors encoding the modified antibodies, and uses thereof. | 04-30-2009 |
20090117031 | Methods for Treating Glioma - The present disclosure provides for method of treatment and/or prevention of disease states that require cystine for maintenance or progression of the disease state. In addition, methods for screening and identifying novel therapeutic agents useful in the treatment of such disease states are described. In one embodiment, the disease state is a cancer, such as, but not limited to, glioma. In this embodiment, methods for the treatment and prevention of glioma by inhibiting cystine uptake or decreasing intracellular cystine concentrations are provided. The present disclosure teaches that glioma cells are dependent on system Xc for cystine uptake. Pharmacological inhibition of system Xc causes a rapid depletion of intracellular glutathione, resulting in decreased cell growth. In contrast, non-malignant astrocytes and cortical neurons remain viable in the presence of Xc inhibitors and continue to take up cystine via alternate amino acid transporters. | 05-07-2009 |
20090117032 | Imaging Agents for Early Detection and Monitoring of Cardiovascular Plaque - The present invention relates in part to imaging agents comprised of a targeting moiety and a label, such as a radionuclide or paramagnetic contrast agent, and methods of use thereof. | 05-07-2009 |
20090117033 | INJECTABLE BIODEGRADABLE PARTICLES - According to an aspect of the invention, injectable polymeric particles are provided that contain a copolymer that contains a hydroxy-acid-based repeat unit selected from a mono(hydroxy acid) unit and a poly(hydroxy acid) unit, an alkyl-ether-based repeat unit selected from a mono(alkyl ether) unit and a poly(alkyl ether) unit, and an acid-based repeat unit selected from a unit comprising multiple carboxylic acid groups and a derivative thereof Other aspects of the invention pertain to methods of making such particles. Still other aspects of the invention pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions. | 05-07-2009 |
20090123365 | Multifunctional nanostructures, methods of synthesizing thereof, and methods of use thereof - A nanostructure and methods of synthesizing same. In one embodiment, the nanostructure includes a nanospecies, a hydrophobic protection structure including at least one compound selected from a capping ligand, an amphiphilic copolymer, and combinations thereof, wherein the hydrophobic protection structure encapsulates the nanospecies, and at least one histidine-tagged peptide or protein conjugated to the hydrophobic protection structure, wherein the at least one histidine-tagged peptide or protein has at least one binding site. | 05-14-2009 |
20090130017 | Targeted short-lived drug delivery - An aspect of the disclosure includes a system for delivering therapeutic agents. In an embodiment, the system includes an implantable medical device comprising at least one reservoir that holds at least one therapeutic agent. Additionally the device includes a delivery mechanism that provides non-systemic in vivo delivery of the at least one therapeutic agent to a local area of an animal in a therapeutically-effective concentration, wherein the therapeutically-effective concentration is in excess of a concentration that would produce a toxic effect when administered systemically to the animal. Furthermore, the at least one therapeutic agent has short half-life. A further aspect of the disclosure includes a method of delivering a therapeutic agent in vivo at non-systemic high doses to a localized area of an animal. | 05-21-2009 |
20090142260 | IN VIVO DETECTION OF APOPTOSIS - The invention provides methods and products, such as kits, useful for determining the apoptotic state of cells in an organism, comprising detecting the presence or abundance of at least one caspase affinity labeling agent in the cells of an animal into which at least one caspase affinity labeling agent has been introduced, wherein the presence or abundance of the caspase affinity labeling agent correlates with the apoptotic state of the cells. | 06-04-2009 |
20090155164 | HUMAN C-FMS ANTIGEN BINDING PROTEINS - Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages. | 06-18-2009 |
20090162275 | CONTRAST AGENTS ANCHORED BY THIOLS ON NANOPARTICLES - The present invention is directed toward a multivalent product including a nanoparticle with a metal, metal alloy, or metal oxide core, a plurality of non-polymerizing ligands bound to the nanoparticle, and a plurality of paramagnetic ions coupled to the nanoparticle by the ligands. Methods of making and using the multivalent product are also disclosed. | 06-25-2009 |
20090162276 | MEDICAL DEVICES CONTAINING MELT-BLOWN NON-WOVENS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF - Continuous processing methods for making absorbable polymeric non-wovens with one or more of the following properties: high burst strength, fine fibers of average diameter from 1 μm to 50 μm, and thickness from 10 μm to 50 mm, have been developed. Improved fiber cohesion is made possible by allowing the fibers of the non-woven to initially remain molten during web collection. In the preferred embodiment, the polymer is a polyhydroxyalkanoate, and in the most preferred embodiment, the polymer comprises 4-hydroxybutyrate. A particularly preferred embodiment is a non-woven of poly-4-hydroxybutyrate or copolymer thereof, wherein the non-woven has a burst strength greater than 0.1 Kgf, wherein the non-woven is derived by a continuous melt-blown process. The non-wovens can be used for a variety of purposes including fabrication of medical devices. | 06-25-2009 |
20090175783 | COMPOUNDS AND IMAGING METHODS - The present invention relates to methods of distinguishing between active and inactive blood clots in vivo, including assisting in the determination of whether it is appropriate or not to continue anticoagulant therapy for an individual patient with previously diagnosed venous thrombo-embolic disease (VTE). | 07-09-2009 |
20090180950 | Polychromatic, diversely-sized particles for angiography - The invention involves polychromatic particles of various sizes for assessing blood flow, blood barrier leakage and blood vessel leakage. | 07-16-2009 |
20090185973 | METHODS, COMPOSITIONS, UNIT DOSAGE FORMS, AND KITS FOR PHARMACOLOGIC STRESS TESTING WITH REDUCED SIDE EFFECTS - Methods are presented for concurrent or sequential administration of pharmaceutical compositions of adenosine, dipyridamole, or combinations thereof, at dosages below the respective single agent doses. Methods are provided for detecting the presence and/or assessing the severity of myocardial ischemia during pharmacologic stress tests. Methods include sequential administration of a dipyridamole bolus followed by intravenous infusion of adenosine and concurrent administration of adenosine and dipyridamole with or without dipyridamole pretreatment. The methods are useful for exploiting the vasodilating abilities of adenosine at doses at which side effects related to adenosine are substantially reduced while optimal coronary artery perfusion is achieved. Also presented are compositions, unit dosage forms, and kits that are useful in performing the methods. | 07-23-2009 |
20090191117 | Anti-Integrin Antibodies, Compositions, Methods and Uses - The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 07-30-2009 |
20090202428 | Use of Dtbz for Imaging Endocrine Pancreas and Beta Cell Mass In Type 1 Diabetes - The present invention provides non-invasive methods for determining the beta cell mass in the pancreas of a subject by administering to the subject an effective amount of a vesicular monoamine transporter type 2 (VMAT2)-specific radioligand; obtaining at least one computerized image of at least a portion of the pancreas of the subject; and quantitatively analyzing the computerized image in order to determine the beta cell mass in the pancreas of the subject. The present invention additionally provides methods for diagnosing a metabolic neuroendocrine disorder in a subject including insulinoma, diabetes and preclinical diabetes, as well as methods for determining the efficacy of treatment for a metabolic disorder. The present invention further provides methods for assessing the prognosis of a subject at risk for developing diabetes, and methods for managing the treatment or prevention of diabetes. The present invention also provides kits for use in determining the beta cell mass in the pancreas of a subject, as well as diagnosing metabolic or neuroendocrine disorders in a subject. | 08-13-2009 |
20090202429 | METHODS FOR TESTING ANTI-THROMBOTIC AGENTS - The invention provides a transgenic non-human animal expressing von Willebrand Factor A1 protein containing at least one mutation selected from the group consisting of: 1263P>S, 1269N>D, 1274K>R, 1287M>R, 1302G>D, 1308H>R, 1313R>W, 1314I>V, 1326R>H, 1329L>I, 1330E>G, 1333A>D, 1344T>A, 1347I>V, 1350T>A, 1370G>S, 1379H>R, 1381T>A, 1385T>M 1391P>Q, 1394A>S, 1397L>F, 1421S>N, 1439L>V, 1442G>S, 1449R>Q, 1466A>P, 1469Q>L, 1472Q>H, 1473V>M, 1475H>Q, 1479S>G, and any combination thereof. | 08-13-2009 |
20090202430 | COMPOSITION FOR CYTOCOMPATIBLE, INJECTABLE, SELF-GELLING POLYSACCHARIDE SOLUTIONS FOR ENCAPSULATING AND DELIVERING LIVE CELLS OR BIOLOGICALLY ACTIVE FACTORS - The present invention provides compositions and methods for tissue repair using a cytocompatible self-gelling cross-linked hydrogel. The composition comprises a biocompatible mixture of chitosan, bifunctional dialdehyde, and hydroxylated polymer, which can be used to immobilize or encapsulate viable cells, or bioactive substances. The method includes the process of mixing bioactive substances, live cells, and/or extracellular matrix components with a cross-linking solution comprising a bifunctional aldehyde-treated hydroxylated polymer such as hydroxyethyl cellulose. The cross-linking solution is then mixed homogenously with a neutral isotonic chitosan solution. The chitosan becomes cross-linked by the bifunctional aldehyde, while the cells are protected from potentially nocive effects of the aldehyde cross-linker by the hydroxylated polymer. The injectable solution retains cell viability and bioactivity, and immobilizes cells at the site of injection or delivery. Depending on the particular application, mixtures of chitosan and bifunctional dialdehyde may be employed. The injectable solution also liberates bioactive substances with controlled release kinetics from the site of injection. | 08-13-2009 |
20090208408 | USE OF VCAM-1 LIGANDS FOR DETECTING AND/OR TREATING CARDIOVASCULAR DISEASES - The invention concerns the use of VCAM-1 ligands in medical imagery, in particular for characterizing and/or therapeutic monitoring of cardiovascular diseases and more particularly for detecting vulnerable coronary atheroma. The invention also concerns the use of VCAM-1 ligands for making a medicine for treating a cardiovascular disease. | 08-20-2009 |
20090220415 | DIAGNOSTIC SYSTEM FOR THE DETECTION OF SKIN CANCER - Methods and compositions are provided for the analysis of skin surfaces to determine the presence of neoplastic tissue. In the methods of the invention, a composition comprising a florescent probe that binds to a specific neoplasia associated marker is applied topically to the area of interest. After topical administration, the probe preferentially binds to markers associated in neoplastic lesions in situ, which binding is detected with a compact illumination unit that provides illumination at a wavelength appropriate for image acquisition. The illumination unit comprises a light source and fiber optic bundle to direct the light towards the area of examination. A detection unit is used to capture and record an image of the area of investigation. The detection unit may be a digital camera, film camera, etc. A mapping module may also be provided to catalogue the site of examination. | 09-03-2009 |
20090238754 | USE OF PYRENE TO CARRY PEPTIDES ACROSS THE BLOOD BRAIN BARRIER - Described are methods for delivering a peptide agent across the blood-brain barrier, comprising administering to a subject a conjugate comprising (i) a peptide agent and pyrene, and related detection and therapeutic methods. | 09-24-2009 |
20090246123 | PHARMACEUTICAL GELS AND METHODS FOR DELIVERING THERAPEUTIC AGENTS TO A SITE BENEATH THE SKIN - Pharmaceutical gels and methods for delivering a therapeutic agent to a target tissue site beneath the skin of a patient are provided, the gel being capable of adhering to the target tissue site and comprising one or more biodegradable depots containing an effective amount of the therapeutic agent. In various embodiments, the gel is sprayable and hardens after contacting the target tissue site. | 10-01-2009 |
20090246124 | HIGH AFFINITY VEGF-RECEPTOR ANTAGONISTS - A cell-based screen is reported can be used to identify specific receptor-binding compounds in a combinatorial library of peptoids (N-alkylglycine oligomers) displayed on beads. This strategy was applied to the isolation of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-binding peptoids, which were optimized to create lead compounds with high affinity for VEGFR2. One of these peptoids was shown to be an antagonist of VEGF-VEGFR2 interaction and receptor function. | 10-01-2009 |
20090252672 | NASAL DELIVERY OF THERAPEUTIC AGENTS USING TIGHT JUNCTION AGONISTS - The invention relates to a therapeutic composition comprising a therapeutically effective amount of one or more therapeutic agents and a nasal mucosa absorption-enhancing amount of one or more tight junction agonists. The invention further relates to a method of treating a subject comprising intranasally administering the composition of the invention to the subject. | 10-08-2009 |
20090252673 | Methods of Making and Using Rubidium-81-Containing Compositions - The present invention relates to preparation of imaging compositions containing Rubidium-81. In addition, the present invention relates to uses of Rubidium-81-containing compositions in diagnostic imaging such as, for example, myocardial imaging. | 10-08-2009 |
20090263317 | METHOD OF SCREENING THE ACTIVITY OF THE SMOOTHENED RECEPTOR TO IDENTIFY THERAPUTIC MODULATION AGENTS OR DIAGNOSE DISEASE - The invention relates to a screening method for the Smoothened receptor for testing compositions as potential Smoothened receptor ligands, either agonist or antagonist activity, by use of an arrestin-reporter molecule conjugate. It also relates to testing cells and individuals by administering a smoothened receptor ligand-reporter molecule conjugate and observing locations where the ligand binds and then using an increased number of surface Smoothened receptors compared to a pre-established criteria as an indication of a cancerous growth or tumor. | 10-22-2009 |
20090280055 | Use of Fluorine-Containing Compounds for Diagnostic Purposes Using Imaging Methods - Use of fluorine-containing compounds for the diagnostic detection of inflammatory processes by means of an imaging method, said inflammatory processes being selected from the group consisting of inflammatory processes of the lymphatic system, such as cancers that directly affect the lymph nodes, especially Hodgkin's disease, non-Hodgkin lymphomas, tumor metastases; liver tumors, inflammatory processes in the border zone of infarctions, such as myocardial infarction and stroke, or tumors; inflammation of organs, such as myocarditis, encephalitis, meningitis (cerebral and spinal meninges); multiple sclerosis; inflammations of the gastrointestinal tract, such as Crohn's disease; inflammation of the vessels, such as arteriosclerosis, especially so-called “vulnerable plaques”; detection of abscesses and arthritis. | 11-12-2009 |
20090285749 | Apparatus and Method for Functional Neurological Screening - A variable focus collimator device and method for functional neurological screening. The variable focus collimator uses sets of corresponding holes in two plates of gamma shielding material, arranged so that only gamma rays emitted from a defined focal region detected. If a suitable radio-labeled tracer has been administered to the patient, this may be used to obtain and compare basal and stimulated data from a small number of regions in the brain to diagnose the presence or absence of dementias. The regions of the brain observer are typically about a cm cubed in volume, and their activity is monitored using small doses (<2 mCi) of radio-labeled, brain perfusion agents. The regions used are easily and repeatably located relative to well-known anthropological and radiological fiducials. By simply use of symmetry, ratios and cortical to cerebellar comparisons, rapid (˜15 minute) screening for dementia may be accomplished. | 11-19-2009 |
20090291047 | Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer - The invention discloses high levels of receptors for | 11-26-2009 |
20090297436 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 12-03-2009 |
20090304575 | IN VITRO METHOD FOR IDENTIFYING COMPOUNDS FOR CANCER THERAPY - The present invention relates to an in vitro method for identifying and evaluating compounds useful in the treatment of different types of cancer, especially lung, breast, colorectal and bladder cancer in an individual, for determining the stage or severity of said cancer in the individual, or for monitoring the effect of the therapy administered to an individual having said cancer; to finding, identifying, developing and evaluating the efficacy of compounds for the therapy of said cancer, for the purpose of developing new medicinal products; as well as to agents inhibiting the expression and/or activity of the choline kinase alpha protein and/or the effects of this expression. | 12-10-2009 |
20090304576 | DEVICE FOR DELIVERY OF ANTI-CANCER AGENTS TO TISSUE - A filament comprising a biocompatible material and a bioactive agent, adapted for implantation within the tissue of a patient wherein the bioactive agent is released over a period of time, is provided. An array of a plurality of the filaments implanted within the tissue of a patient, an array assembler, and a matrix comprising a plurality of filaments and a base adapted for implantation within the tissue of a patient, are further provided. A method for treatment of a malcondition in a patient comprises implantation of a filament, an array of filaments, or a matrix. The bioactive agent can be a chemotherapeutic agent or a radiotherapeutic agent. A radiotherapeutic agent is 123I- or 125I-IUDR, for example in treatment of an advanced stage localized brain tumor such as glioblastoma multiforme. | 12-10-2009 |
20090311172 | Massage cream and massaging method using the same - The present invention relates to a massage cream which contains 5.0 Bq to 300.0 Bq of powders of one or more radioactive materials per 1 g of base materials. Furthermore in the massage cream the radioactive materials include 4.0 Bq to 240.0 Bq of thorium. Moreover in the massage cream the radioactive materials further include 1.0 Bq to 60.0 Bq of uranium. With the massage cream, medical effects can be given to the body of a person. | 12-17-2009 |
20090311173 | METHOD AND DEVICE FOR RADIOTHERAPY - A radiotherapy method, comprising positioning a predetermined amount of a radionuclide selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220, in proximity to and/or within a tumor of a subject, for a predetermined time period. The predetermined amount and the predetermined time period are selected sufficient for the radionuclide to administering a predetermined therapeutic dose of decay chain nuclei and alpha particles into the tumor. | 12-17-2009 |
20090324489 | Wortmannin conjugates and uses thereof - The invention features conjugates of wortmannin, and wortmannin derivatives, and their use as inhibitors of PI3-kinase activity in treating cancer, inflammatory diseases, and | 12-31-2009 |
20100015041 | Class of Supramolecular Drug Molecules and Methods of Identification and Use Thereof - This invention provides a class of supramolecular drugs and methods of identifying and using such drugs | 01-21-2010 |
20100015042 | Combine radiation therapy and chemotherapy for treating cancer - A method of treating a tumor of a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of alpha particles and a chemotherapeutic agent, wherein the alpha particles are administered by positioning a non-stable alpha-emitting radionuclide in proximity to and/or within the tumor, so as to administer a dose of alpha particles into the tumor, wherein the method does not comprise administration of an inhibitor of DNA repair, thereby treating the tumor of the subject. | 01-21-2010 |
20100015043 | CYTOCHROME C ACETYLATION - Modulation of cytochrome c acetylation, e.g., with a SIR polypeptide, enables interventions that modulate lifespan regulation and cell proliferation, e.g., by modulating apoptosis and/or mitochondrial function such as respiration. | 01-21-2010 |
20100021378 | IMAGING PROTOCOLS - Protocols for radioimaging an event or disorder are provided. An exemplary protocol comprises a method of radioimaging a myocardial perfusion, the method comprising in sequence:
| 01-28-2010 |
20100034734 | SYSTEM AND METHOD FOR QUANTITATIVE MOLECULAR BREAST IMAGING - A system and method for performing quantitative lesion analysis in molecular breast imaging (MBI) using the opposing images of a slightly compressed breast that are obtained from the dual-head gamma camera. The method uses the shape of the pixel intensity profiles through each tumor to determine tumor diameter. Also, the method uses a thickness of the compressed breast and the attenuation of gamma rays in soft tissue to determine the depth of the tumor from the collimator face of the detector head. Further still, the method uses the measured tumor diameter and measurements of counts in the tumor and background breast region to determine relative radiotracer uptake or tumor-to-background ratio (T/B ratio). | 02-11-2010 |
20100040537 | Prostaglandin E2 Binding Proteins and Uses Thereof - The present invention encompasses prostaglandin E | 02-18-2010 |
20100047162 | METHODS OF PROCESSING MULTI-PHASIC DISPERSONS - A method for processing multi-phasic dispersions is provided. The method comprises providing a multi-phasic dispersion including dispersed and continuous phases, providing a non-solvent, combining the multi-phasic dispersion and the non-solvent, and selectively effecting migration of the dispersed phase into or through the non-solvent such that the microparticles are separated from the dispersion. | 02-25-2010 |
20100055032 | METHODS FOR VASCULAR IMAGING USING NANOPARTICULATE CONTRAST AGENTS - New and sensitive methods for imaging the perfusion of tissues and the extravasation of blood out vessels have been developed. The present invention is useful in the imaging of microperfusion in organ tissues (e.g., heart, liver, brain and kidneys) to aid in evaluating the perfusion status of organs on the level of the smallest blood vessels (i.e. capillaries). The present invention also provides methods and compositions for imaging and evaluating macrophages and plaque, e.g., vulnerable plaque. Such evaluations are important in a number of clinical diagnoses, including assessing organ damage associated with angina pectoris, heart attack, stroke, and the like, as well as assessing vessel leakages associated with aneurisms, diffuse bleedings after trauma, and the like. | 03-04-2010 |
20100074840 | Anthracycline-Antibody Conjugates for Cancer Therapy - The invention relates to therapeutic conjugates with the ability to target various antigens. The conjugates contain a targeting antibody or antigen binding fragment thereof and an anthracycline chemotherapeutic drug. The targeting antibody and the chemotherapeutic drug are linked via a linker comprising a hydrazide moiety. | 03-25-2010 |
20100080756 | METHODS FOR PROTECTING AND REGENERATING BONE MARROW USING CXCR3 AGONISTS AND ANTAGONISTS - CXCR3 agonists, including natural CXCR3 ligands, promote bone marrow regeneration, increase peripheral white blood cells, and increase survival if administered prior to treatment of a subject with chemotherapy or radiotherapy. Similar effects are obtained by administering an CXCR3 antagonists following chemotherapy radiotherapy. Compositions and methods are presented for the treatment of cancer and bone marrow diseases. | 04-01-2010 |
20100098624 | METHOD FOR USING CDO ANTAGONISTS TO MODULATE HEDGEHOG SIGNALING - The present invention provides for a method of using BOC/CDO hedgehog antagonists to inhibit hedgehog signaling, as well as treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders, as well as other conditions affected by hedgehog signaling such as hair growth, neural stem cell differentiation, chondrogenesis and osteogenesis, lung surfactant production, formation of lamellated bodies in lung cells. | 04-22-2010 |
20100104501 | PRSS23 AS A BIOMARKER, THERAPEUTIC AND DIAGNOSTIC TARGET - The invention provides PRSS23, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PRSS23 as well as pharmaceutical compositions comprising such compounds. The invention also provides PRSS23 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. | 04-29-2010 |
20100104502 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING ENDOTHELIAL DYSFUNCTION - The present invention relates to endothelial dysfunction. In particular, the present invention provides biomarkers of endothelial dysfunction (e.g., vascular disease), and compositions and methods of using the same. Compositions and methods of the present invention find use in, among other things, research, clinical, diagnostic, drug discovery, and therapeutic applications. | 04-29-2010 |
20100104503 | MODULAR NANOPARTICLES FOR ADAPTABLE VACCINES - Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and subtraction of antigen, adjuvant, immune potentiators, molecular recognition and transport mediation elements, as well as intracellular uptake mediators, allows for exquisite control over variables that are important in optimizing an effective vaccine delivery system. | 04-29-2010 |
20100104504 | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation - The subject invention concerns materials and methods for treating and/or preventing diseases associated with accumulation of Aβ peptide in neural tissue. The subject invention also concerns materials and methods for treating and/or preventing stress disorders, such as post-traumatic stress disorder (PTSD). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of cotinine, or a pharmaceutically acceptable salt thereof, to a person or animal in need of treatment. The methods of the invention can be used to prevent and/or treat Alzheimer's disease, Parkinson's disease, and/or Down's syndrome. The subject invention also concerns compositions that comprise cotinine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or adjuvant. | 04-29-2010 |
20100104505 | System and Method for Quantitative Molecular Breast Imaging - A system and method for performing quantitative lesion analysis in molecular breast imaging (MBI) using the opposing images of a slightly compressed breast that are obtained from the dual-head gamma camera. The method uses the shape of the pixel intensity profiles through each tumor to determine tumor diameter. Also, the method uses a thickness of the compressed breast and the attenuation of gamma rays in soft tissue to determine the depth of the tumor from the collimator face of the detector head. Further still, the method uses the measured tumor diameter and measurements of counts in the tumor and background breast region to determine relative radiotracer uptake or tumor-to-background ratio (T/B ratio). | 04-29-2010 |
20100104506 | Nanoparticle-Coated Medical Devices And Formulations For Treating Vascular Disease - Nanoparticle-coated medical devices, nanoparticle-containing formulations and methods of using for treating a vascular disease are disclosed. The medical device includes a coating that comprises a plurality of nanoparticles, wherein the nanoparticles comprise one or more bioactive agents encapsulated within, adhered to a surface of or integrated into the structure of the nanoparticles and further comprise one or more contrast enhancing agents encapsulated within, adhered to a surface of or integrated into the structure of the nanoparticles. | 04-29-2010 |
20100111829 | FLOWABLE COMPOSITION THAT HARDENS ON DELIVERY TO A TARGET TISSUE SITE BENEATH THE SKIN - Flowable compositions and methods are provided for delivering a therapeutic agent at or near a target tissue site beneath the skin of a patient, the flowable composition comprising (i) a solvent and (ii) an effective amount of the therapeutic agent, the flowable composition being capable of hardening to form a drug depot at a physiological temperature or as solvent contacts bodily fluid at or near the target tissue site, wherein the drug depot is capable of releasing the therapeutic agent over a period of at least one day and the target tissue site comprises at least one muscle, ligament, tendon, cartilage, spinal disc, spinal foraminal space near the spinal nerve root, facet or synovial joint, or spinal canal. In some embodiments, an implantable drug depot for delivering a therapeutic agent is provided, the implantable drug depot comprising (i) a chamber; and (ii) a flowable composition comprising an effective amount of a therapeutic agent disposed within the chamber of the drug depot, the flowable composition capable of hardening when the drug depot is delivered at or near the target tissue site. | 05-06-2010 |
20100111830 | Compositions and methods for surface abrasion with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111831 | Compositions and methods for surface abrasion with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111832 | Compositions and methods for surface abrasion with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111833 | Compositions and methods for surface abrasion with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111834 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111835 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111836 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111837 | Compositions and methods for biological remodeling with frozen particle compositions - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111838 | BRAIN-LOCALIZING POLYPEPTIDES COMPRISING A MULTIVALENT BINDING MOIETY AND IMPROVED METABOLIC STABILITY - Brain-localizing polypeptides carrying a reactive group for linking to a molecule that does not have brain-localizing activity were successfully produced by introducing at least two lysine residues into cyclized polypeptides having a brain-localizing motif sequence. These polypeptides have improved metabolic stability compared to conventional brain-localizing polypeptides, and can efficiently translocate desired molecules into the brain. | 05-06-2010 |
20100111839 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION - An agent for inhibiting P-glycoproteins comprises a non-natural adenine ribose analog. | 05-06-2010 |
20100119443 | RADIOTHERAPEUTIC SYSTEM AND METHOD PERFORMED BY NON-INVASIVE AND REAL-TIME TUMOR POSITION TRACKING - A radiotherapeutic system including non-invasive and real-time tumor tracking includes: a signal detector for detecting radioactive rays emitted from a tumor to which the radioactive medical supply is adsorbed and generating an electrical signal; a signal processor for converting the electrical signal generated into a three-dimensional (3D) coordinate signal; a controller for generating a control signal in conjunction with the 3D coordinate signal output by the signal processor; and a radioactive-ray irradiation device for emitting radioactive rays to the tumor, wherein the amount of the radioactive rays is controlled by the controller. | 05-13-2010 |
20100135900 | CD37 IMMUNOTHERAPEUTIC COMBINATION THERAPIES AND USES THEREOF - The present disclosure provides methods for using CD37-specific binding molecules (such as a CD37-specific SMIP or antibody) in combination with mTOR inhibitors (such as rapamycin and derivatives or analogues thereof) or phosphatidylinositol 3-kinase (PI3K) inhibitors (such as p110δ-specific inhibitors or the like), which can be done concurrently or sequentially, to treat or prevent a B-cell related hyperproliferative disease, such as a lymphoma, carcinoma, myeloma, or the like. | 06-03-2010 |
20100135901 | COMBINATION THERAPY - The invention provides combination treatments with IL-21, analogues and derivatives thereof. | 06-03-2010 |
20100143241 | Method and apparatus for delivery of agents across the blood brain barrier - We describe a method for opening the blood-brain barrier (BBB) using ultrasound and preformed microbubbles. With this method, diagnostic or therapeutic agents may be administered to the brain. This method can open a focal region of the BBB and administer agents in a targeted fashion or the method can open large regions (or the entirety) of the brain for more global administration of agents. In one embodiment, the method can be used to administer contrast agents (e.g., agents that increase or decrease the magnetic resonance imaging signal) to the brain and thereby improve the quality or information content of imaging data. In another embodiment, a standard clinical diagnostic ultrasound scanner can be used to open specific regions of the BBB and administer diagnostic or therapeutic agents. Importantly, this invention can open the BBB in a non-destructive/non-invasive fashion, allowing the subject to be awake and suffer no detectable side effects. | 06-10-2010 |
20100150827 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER - The invention is directed to a Compound of Formula I, II, or III. The invention provides compounds that inhibit, regulate, and/or modulate PI3K that are useful in the treatment of hyperproliferatives diseases, such as cancer. | 06-17-2010 |
20100158795 | METHODS AND SYSTEMS FOR ASSESSING LUNG FUNCTION AND DELIVERING THERAPEUTIC AGENTS - Methods and systems for isolating, assessing and treating lung compartments are disclosed. One or more lung compartments are accessed through an isolation catheter, oxygen rich gas is delivered to the compartments, and blood oxygen or exhaled carbon dioxide are monitored to assess lung compartment function. Diseased lung compartments may be treated using therapeutic agents delivered to the diseased compartments through the isolation catheter. Therapeutic agents include carbon monoxide, radioactive agents, chemotherapeutic agents or angiogenesis inhibitors and angiocidal agents. | 06-24-2010 |
20100158796 | AMIDES OF HYALURONIC ACID AND THE DERIVATIVES THEREOF AND A PROCESS FOR THEIR PREPARATION - An amide of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of general formula (1).: wherein R═NR | 06-24-2010 |
20100158797 | USE OF A2A ADENOSINE RECEPTOR AGONISTS - Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A | 06-24-2010 |
20100158798 | FP-Pocket-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity - The present invention embraces compounds selected for interacting with the Fingers-Palm pocket of telomerase and use thereof for modulating the activity of telomerase and preventing or treating diseases or conditions associated with telomerase. | 06-24-2010 |
20100158799 | METHOD AND COMPOSITION FOR BIOACTIVE AGENT RELEASE IN VIVO - A composition for bioactive agent release in vivo. The composition includes the bioactive agent in combination with a mixture of a first polymer component such as poly(butyl methacrylate) and a second polymer component such as poly(ethylene-co-vinyl acetate). | 06-24-2010 |
20100166649 | METHOD TO INHIBIT CANCER TARGETING CD24 - The present invention relates to a method to inhibit cancer by targeting CD24, more precisely a method to inhibit cancer by using CD24 expressed in most cancer cells as a target of an antibody therapeutic agent or by inhibiting the interaction between CD24 and P-selectin. CD24 is over-expressed in most cancer cells and CD24 accumulated in cytoplasm accelerates metastasis. Therefore, the method to inhibit cancer of the invention by targeting CD24 can be effectively used for the treatment of cancer by inhibiting the progress of various cancers over-expressing CD24. | 07-01-2010 |
20100166650 | MOLECULAR IMAGING OF LIVING SUBJECTS USING RAMAN SPECTROSCOPY AND LABELED RAMAN NANOPARTICLES - Methods of imaging a living host using Raman nanoparticles; methods of generating a true image of a living host having been administered Raman nanoparticles; methods of multiplex imaging of a living host using a plurality of Raman nanoparticles; methods of generating multimodality images by combining Raman images with other functional/anatomical images; labeled Raman nanoparticles; and the like, are provided. | 07-01-2010 |
20100172829 | ENHANCED CARRIERS FOR THE DELIVERY OF MICROPARTICLES TO BODILY TISSUES AND FLUIDS - Improved compositions for tissue augmentation are provided. These compositions comprise an amount of crosslinked material sufficient to provide a melt temperature (T | 07-08-2010 |
20100183501 | Medical Devices With Nanotextured Titanium Coating - A system for treating a vascular condition includes a catheter, a stent disposed on the catheter, the stent having a stent framework including a core, the core having an outer surface and a pure titanium layer deposited on the outer surface of the core and a nanotextured surface formed in the deposited pure titanium layer. A method of manufacturing a stent for treating a vascular condition includes depositing a uniformly dense and uniformly thick layer of pure titanium onto an outer surface of a stent framework core, placing stent framework into a running chamber having a cathode and electrolyte solution, connecting stent framework and cathode to a power source operably connected to the running chamber, applying a power source to the attached stent framework and cathode for a predetermined length of time and at a predetermined voltage and forming a nanotextured surface within the deposited titanium layer. | 07-22-2010 |
20100183502 | Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials - Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound. | 07-22-2010 |
20100183503 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS - A myocardial imaging method that is accomplished by administering one or more adenosine A | 07-22-2010 |
20100189641 | Novel Strategies for Improved Cancer Vaccines - The present invention concerns methods and compositions for forming anti-cancer vaccine complexes. In preferred embodiments, the anti-cancer vaccine complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the vaccine complex. The anti-cancer vaccine complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138 | 07-29-2010 |
20100196264 | USE OF SOMATOSTATIN ANALOGS IN MYOCARDIAL PERFUSION IMAGING - The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides of the invention to said subject. | 08-05-2010 |
20100209340 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER - The invention is directed to Compounds of Formula (I). The invention provides compounds that inhibit, regulate, and/or modulate P13K that are useful in the treatment of hyperproliferative diseases, such as cancer. | 08-19-2010 |
20100221175 | Antibody Therapy - The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition. | 09-02-2010 |
20100226852 | CLK-PEPTIDE AND SLK-PEPTIDE - The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment. | 09-09-2010 |
20100247427 | Methods of inhibiting cell growth and methods of enhancing radiation responses - Provided herein are methods of enhancing the radiation response of a cell expressing activated Stat1, Stat3, or Stat5. Methods for synergistically affecting a cell expressing activated Stat1, Stat3, or Stat5 are also described. The described methods may also be used to synergistically affect or enhance the radiation response of a cell in a subject. | 09-30-2010 |
20100247428 | USES OF RARE EARTH ELEMENTS FOR HAIR IMPROVEMENT - Disclosed are uses of rare earth element selected from the group consisting of cerium (Ce), praseodymium (Pr), promethium (Pm), europium (Eu), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), scandium (Sc), yttrium (Y), lanthanum (La), neodymium (Nd), samarium (Sm), gadolinium (Gd), ruthenium (Lu) and mixtures thereof, or a salt or an oxide thereof for preventing hair loss, promoting hair regrowth and hair growth, removing and preventing dandruff, or promoting black hair formation. | 09-30-2010 |
20100247429 | MICROCHIP, MICROCHIP DEVICE AND EVAPORATION METHOD USING MICROCHIP - Provided is a microchip capable of integrating liquid evaporation as an operation on the microchip. In the microchip | 09-30-2010 |
20100272635 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN OVARIAN CANCER AND LUNG CANCER - Methods and compositions for diagnosis, prognosis and monitoring of ovarian cancer and lung cancer are provided. Assays that detect NHERF-I (or one or more markers related thereto) and NHERF-I-containing complexes are used to assign a diagnosis to a subject being assessed for the presence of ovarian or lung cancer; assign a prognostic risk to a subject suffering from ovarian or lung cancer; or monitor the course of ovarian or lung cancer treatment in a subject. | 10-28-2010 |
20100278724 | INHIBITION OF MIGRATION AND INDUCTION OF CELL DEATH BY THE TYPE II COLLAGEN AMINO PROPEPTIDES - The present invention provides combinations and methods for inducing cell death, inhibiting angiogenesis, and inhibiting cell migration. In particular, the present invention provides methods for inducing cell death in a cell expressing an αvβ3 and/or an αvβ5 integrin. | 11-04-2010 |
20100284905 | Methods and Agents for Inhibiting Tumor Growth by Targeting the SSDNA Replication Intermediate of Tumor Stem Cells - The application is based on the observation that tumor stem cell (TSC) replication involves a replicative intermediate configuration wherein a substantial fraction of the TSC genome is present as single-stranded DNA (ssDNA) when bell-shaped nuclei commence separation into two nuclei. During this replicative intermediate configuration large amounts of ssDNA are thus present in the nuclei of cells which the applicant proposes as target for anti-tumor therapy. A method of screening for anti-tumorigenic agents targeting ssDNA and use of such agents in therapy is claimed. | 11-11-2010 |
20100290982 | SOLID IN OIL/WATER EMULSION-DIFFUSION-EVAPORATION FORMULATION FOR PREPARING CURCUMIN-LOADED PLGA NANOPARTICLES - The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and places the targeting agent on the exterior surface of a biodegradable nanoparticle, wherein an active agent is encapsulated in or about the nanoparticle. | 11-18-2010 |
20100303714 | ONCOLYTIC VACCINIA VIRUS CANCER THERAPY - Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject administered at least 1×108 viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor. | 12-02-2010 |
20100303715 | Prostate-specific membrane antigen and uses thereof - This invention provides an isolated mammalian nucleic acid molecule encoding an alternatively spliced prostate-specific membrane (PSM′) antigen. | 12-02-2010 |
20100303716 | SWITCHABLE NANO-VEHICLE DELIVERY SYSTEMS, AND METHODS FOR MAKING AND USING THEM - The invention provides nanodevices or products of manufacture for use as drug delivery vehicles. In one aspect, the invention provides nanodevices or products of manufacture having on-off release mechanisms, e.g., that are “switchable”, or “actuatable” (for example magnetically or ultrasonically switchable), for compounds contained within, e.g., for use as drug delivery nano-vehicles having on-off drug release mechanisms, and their therapeutic applications. | 12-02-2010 |
20100303717 | Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials Cross Reference to Related Applications - Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound. | 12-02-2010 |
20100303718 | Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials - Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound. | 12-02-2010 |
20100310450 | METHOD OF DIAGNOSIS AND AGENTS USEFUL FOR SAME - The present invention relates generally to a method of screening for a neoplastic cell in a subject. More particularly, the present invention provides a method of screening for both viable neoplastic cells and, still further, cytotoxin induced neoplastic cell death by detecting the level of expression of La protein and/or gene by a cellular population in said subject or in a biological sample derived from said subject. The method of the present invention is useful in a range of applications including, but not limited to, diagnosing, prognosing or assessing a neoplastic condition, monitoring the progression of such a condition, assessing the effectiveness of a therapeutic agent or therapeutic regime and predicting the likelihood of a subject either progressing to a more advanced disease state or entering a remissive state. The present invention also provides diagnostic agents useful for detecting La protein and/or nucleic acid molecules. | 12-09-2010 |
20100310451 | ALTERED N-CADHERIN PROCESSING IN TUMOR CELLS BY FURIN AND PROPROTEIN CONVERTASE 5A (PC5A) - The present invention relates to a method for diagnosis and/or prognosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a subject by determining the molecular form of cadherin at the cell surface of cancer cells in the subject. The invention also relates to a method for preventing, inhibiting or treating cancer or its metastasis in a subject by increasing the adhesive forms of cadherin and/or decreasing the non-adhesive forms of cadherin at the cell surface. The invention also relates to a method step of determining the expression level of furin and proprotein convertase 5A (PC5A). | 12-09-2010 |
20100316563 | Method For The Preparation Of New Oligoclonal Antibodies - A process is provided for the preparation of antibodies or fragments thereof using a prokaryotic host cell containing DNA sequences encoding for said antibodies of fragments thereof, wherein said DNA sequence is derived from a coronary plaque sample. Compositions containing said antibodies are also provided. Ligands to said antibodies and compositions containing said ligands are also described. | 12-16-2010 |
20100322849 | ENHANCED B CELL CYTOTOXICITY OF CDIM BINDING ANTIBODY - Formulations and methods of treating human patients suffering from a condition characterized by lymphoid cancer, autoimmune disease or B cell hyperproliferation are disclosed, the treatment comprising administering (1) a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell, and (2) a cytotoxic agent, including a chemotherapeutic agent, radioactive isotope, cytotoxic antibody, immunoconjugate, ligand conjugate, immunosuppressant, cell growth regulator and/or inhibitor, toxin, or mixtures thereof, including agents that disrupt the cytoskeleton of B cells, particularly vinca alkaloids or colchicine. | 12-23-2010 |
20100322850 | NEW PLASMA MEMBRANE BIOMARKERS PREFERENTIALLY EXPRESSED IN PANCREATIC BETA CELLS USEFUL IN IMAGING OR TARGETING BETA CELLS - The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. It was selected by a Systems Biology approach on Massively Parallel Signal Sequencing datasets obtained in human islets and Affymetrix microarray datasets on human islets, purified rat primary beta and non beta cells and insulinoma cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1 D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration). The five specific features of the selected biomarkers are: 1) Preferentially expressed in pancreatic islets as compared to surrounding tissues; 2) Higher expression in pancreatic beta cells than in pancreatic alpha cells or than in other islet non-beta cells; 3) Expression levels in pancreatic beta cells are higher or comparable to glucokinase which is an enzyme specifically expressed in the pancreatic beta cell; 4) Located in the membrane and as such targetable with antibodies, peptides or small molecules which allows imaging, targeting and immunohistochemistry; and 5) Expression is not induced during the process of inflammation of the beta cell mass and the protein is not enriched in T-cells and dendritic cells or in other cells participating in the inflammation process. | 12-23-2010 |
20100322851 | KID3 and KID3 Antibodies That Bind Thereto - The invention provides the identification and characterization of disease and cancer-associated epitope, KID3. The invention also provides a family of monoclonal antibodies that bind to KID3, methods of diagnosing and treating various human cancers and diseases that express KID3. | 12-23-2010 |
20100322852 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS - Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions. | 12-23-2010 |
20100322853 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS - Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions. | 12-23-2010 |
20100329976 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS - Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions. | 12-30-2010 |
20110002843 | METHOD OF DETECTING MYOCARDIAL DYSFUNCTION IN PATIENTS HAVING A HISTORY OF ASTHMA OR BRONCHOSPASM - This invention is directed to myocardial imaging of human patients having a history of asthma or bronchospasm. In particular, the present invention uses binodenoson as a pharmacological stressor in conjunction with any one of several noninvasive and invasive diagnostic procedures available. For example, intravenous administration may be used in conjunction with a radiopharmaceutical agent and myocardial perfusion imaging to assess the severity of myocardial ischemia. | 01-06-2011 |
20110014117 | ANTI-IGF1R - The present invention relates in part to anti-IGF1R antibodies and antigen-binding compositions thereof along with methods of use thereof. For example, methods of treating medical disorders such as cancer are covered. | 01-20-2011 |
20110014118 | Nanotherapeutic colloidal metal compositions and methods - The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, the nanotherapeutic compositions of the present invention comprise a platform comprising a colloidal metal, a targeting ligand such a tumor necrosis factor, a stealth agent such as polyethylene glycol, and one or more diagnostic or therapeutic agents for delivery. The invention also comprises methods and compositions for making such nanotherapeutic compositions and for the treatment of cancer. | 01-20-2011 |
20110020216 | SCAFFOLDS FOR CELL COLLECTION OR ELIMINATION - A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host. | 01-27-2011 |
20110020217 | TREATMENT OF MELANOMA - There is described a pharmaceutical composition comprising dexanabinol, or a derivative thereof, in combination with a second therapeutic agent that targets BRAF or MEK, and a pharmaceutically acceptable adjuvant, diluent or carrier. There is also described a method of treating a patient suffering from melanoma and uses related thereto. | 01-27-2011 |
20110020218 | NOVEL ANTI CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. | 01-27-2011 |
20110033376 | Treatment of Melanoma - There is described dexanabinol, or a derivative thereof, for the treatment of melanoma. There is also described a method of treating a patient suffering from melanoma. | 02-10-2011 |
20110033377 | ASSAY TO DETECT A GYNECOLOGICAL CONDITION - The present invention relates generally to the field of diagnostic and prognostic assays for a gynecological condition. More particularly, the present invention provides an assay for diagnosing the presence of or a risk of having a gynecological cancer or a sub-type thereof or a stage of the cancer or complications arising therefrom or other gynecological condition including an inflammatory disorder. | 02-10-2011 |
20110044892 | FORMULATION AND METHOD FOR TREATMENT OF TEETH - Tooth dentin is treated by applying thereto a paste or other solution to effect plugging of the tubules to eliminate or reduce tooth sensitivity. The solution may be applied to other tooth components for treatment thereof. The solution has a lanthanide salt dissolved therein and a pH between about 6 and 7 and includes an agent for bulking so as to enhance the plugging effect. A dental restoration has incorporated therein lanthanide ions. | 02-24-2011 |
20110044893 | VASCULAR TARGETS FOR DETECTING, IMAGING AND TREATING NEOPLASIA OR NEOVASCULATURE - Methods of delivering an agent in a tissue-specific manner, by targeting annexin A1, a derivative of annexin A1, or a binding partner of annexin A1, are described. The methods can be used for detecting, imaging and/or treating neoplasia, angiogenesis or neovasculature, as well as for diagnostics and methods of assessing treatment efficacy. Antibodies to annexin A1 are also described, as are methods screening for agents altering annexin A1 activity. | 02-24-2011 |
20110044894 | Immunoglobulin and/or Toll-Like Receptor Proteins Associated with Myelogenous Haematological Proliferative Disorders and Uses Thereof - The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for members of the immunoglobulin (Ig) and/or toll-like receptor superfamilies that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells. | 02-24-2011 |
20110044895 | METHODS AND COMPOSITIONS FOR REDUCING STEMNESS IN ONCOGENESIS - The invention provides methods and compositions for reducing the number of cancer stem cells in a mixed population of differentiated cells (for example, cancer cells) and cancer stem cells. The cancer stem cells, if present, can be more resistant to traditional drug-based therapies and can provide a source for new, differentiated cancer cells associated with the development of drug-resistance and more aggressive phenotypes. When combined with traditional cancer therapies, for example, drug-based therapies, the methods and compositions of the invention provide a more effective way for treating cancer and can provide a model system for developing new cancer therapies and new treatment modalities. | 02-24-2011 |
20110059010 | DUAL PHASE DRUG RELEASE SYSTEM - The present invention relates to conjugate comprising a carrier substituted with one or more occurrences of a moiety having the structure (I): wherein each occurrence of M is independently a modifier having a molecular weight ≦10 kDa; denotes direct of indirect attachment of M to linker L | 03-10-2011 |
20110064650 | MICROORGANISMS FOR PREVENTING AND TREATING NEOPLASMS ACCOMPANYING CELLULAR THERAPY - Provided are methods for using cellular compositions in combination with oncolytic viruses. The methods include administering oncolytic viruses for the inhibition and treatment of tumors caused by administration of cellular therapies, such as stem cell therapies. The methods also include contacting cellular compositions with oncolytic viruses for the removal of neoplastic cells prior to administration of the cellular composition for therapy. Diagnostic methods for monitoring treatment also are provided. | 03-17-2011 |
20110064651 | RECOMBINANT NUCLEOTIDE SEQUENCE, CELL OR VECTOR CONTAINING THE SAME AND METHOD FOR USING CELL CONTAINING THE SAME TO ENCODE ANTI-POLYETHYLENE GLYCOL MONOCLONAL ANTIBODIES - The invention provides a recombinant nucleotide sequence, including the sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, wherein the recombinant nucleotide sequence encodes an anti-polyethylene glycol recombinant single chain membrane antibody. | 03-17-2011 |
20110064652 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS TO THE LUNG - The present invention concerns a delivery system administered to the lung preferably by inhalation comprising a polymer-based nanoparticle; and a linker comprising a first portion non-covalently anchored to said nanoparticle, wherein at least part of said first portion comprises a hydrophobic/lipophilic segment embedded in said nanoparticle; and a second portion comprising a coupling group, preferably a maleimide compound, exposed at the outer surface of said nanoparticle. In accordance with one embodiment, the delivery system comprises one or more targeting agents, each covalently bound to said coupling group, preferably maleimide compound, and is administered as an aerosol in the therapy or diagnosis of lung cancer or bronchial dysplasia. In accordance with yet another embodiment, the delivery system comprises a drug and/or a radiopharmaceutical and/or a contrasting agent. A specific example for a linker in accordance with the invention is octadecyl-4-(maleimideomethyl)cyclohexane-carboxylic amide (OMCCA). | 03-17-2011 |
20110076230 | Novel Substituted Indoles - The present invention relates to novel amyloid binding compounds and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study amyloid deposits in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel amyloid binding compounds as a diagnostic. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted indole derivatives, compositions, and therapeutic uses and processes for making such compounds. | 03-31-2011 |
20110085968 | ARTICLES COMPRISING NANO-MATERIALS FOR GEOMETRY-GUIDED STEM CELL DIFFERENTIATION AND ENHANCED BONE GROWTH - The present invention provides articles of manufacture comprising biocompatible nanostructures comprising significantly increased surface area for, e.g., organ, tissue and/or cell growth, e.g., for bone, tooth, kidney or liver growth, and uses thereof, e.g., for in vitro testing of drugs, chemicals or toxins, or as in vivo implants, including their use in making and using artificial tissues and organs, and related, diagnostic, screening, research and development and therapeutic uses, e.g., as drug delivery devices. The present invention provides biocompatible nanostructures with significantly increased surface area, such as with nanotube and nanopore array on the surface of metallic, ceramic, or polymer materials for enhanced cell and bone growth, for in vitro and in vivo testing, cleansing reaction, implants and therapeutics. The present invention provides optically transparent or translucent cell-culturing substrates. The present invention provides biocompatible and cell-growth-enhancing culture substrates comprising elastically compliant protruding nanostructure substrates coated with Ti, TiO | 04-14-2011 |
20110091372 | Dual Variable Domain Immunoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 04-21-2011 |
20110091373 | PAA NANOPARTICLES FOR ENHANCEMENT OF TUMOR IMAGING - A composition comprising PAA nanoparticles containing a post loaded tetrapyrollic photosensitizer and an imaging agent and methods for making and using same. | 04-21-2011 |
20110091374 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING - The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-I, and an imaging moiety, and scanning the subject using diagnostic imaging. | 04-21-2011 |
20110091375 | USE OF THE COMBINATION COMPRISING TEMOZOLOMIDE AND TNF-ALPHA FOR TREATING GLIOBLASTOMA - Disclosed are methods of synergistically inhibiting growth of a glioma cell comprising contacting the cell with temozolomide and TNFα, or with temozolomide, TNFα, and radiation. Also disclosed are methods of synergistically inhibiting growth of a glioma in a human cancer patient comprising administering temozolomide and TNFα, or with temozolomide, TNFα, and radiation. Pharmaceutical combinations and therapeutic combinations suitable for use in the methods of the invention are also disclosed. | 04-21-2011 |
20110104049 | METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION - The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred embodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers. | 05-05-2011 |
20110104050 | Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin - Screening and diagnostic reagents, kits and methods for primary and/or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach or esophageal cancer are disclosed. | 05-05-2011 |
20110110850 | COMPOUNDS FOR THERAPY AND DIAGNOSIS - The present invention relates to a transition metal complex represented by Formula (I) or salts thereof, or to a ligand represented by Formula (H) or salts thereof, wherein X represents a transition metal, preferably Pt, and methods for their use and preparation. In particular, the invention relates to compounds which may possess useful therapeutic activity in treating amyloid diseases, and in particular, Alzheimer's disease. The invention also relates to the use of these compounds in methods of therapy, and diagnosis, and the manufacture of medicaments as well as compositions containing these compounds. | 05-12-2011 |
20110110851 | Multivalent Immunoglobulin-Based Bioactive Assemblies - The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and/or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and/or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and/or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and/or diagnostic agents. | 05-12-2011 |
20110117008 | USE OF AVICINS TO DELIVER THERAPEUTIC AND DIAGNOSTIC AGENTS - The present invention provides compositions of avicins and avicin mixtures that enhance topical, percutaneous, transmucosal, transepithelial, transendothelial or transdermal transport of agents including diagnostic molecules, therapeutic drugs and cosmetic materials. | 05-19-2011 |
20110117009 | DRUG CONJUGATES WITH POLYGLYCEROLS - The present invention relates to a drug polymer conjugate comprising a pharmaceutically active compound and a dendritic polyglycerol, as well as to a drug polymer conjugate comprising a pharmaceutically and/or diagnostically active compound bound to a dendritic polyglycerol core having a polyethylene glycol shell. | 05-19-2011 |
20110117010 | Methods and Compositions for Administering Therapeutic and Diagnostic Agents - Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities. | 05-19-2011 |
20110117011 | NEUTRALIZING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) VARIANTS AND USES THEREOF - Neutralizing PCSK9 variants that interact with low density lipoprotein receptor (LDLR) are described. Methods and compositions for treating disorders by administering a pharmaceutically effective amount of a neutralizing PCSK9 variant are described. | 05-19-2011 |
20110123434 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER - The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments. | 05-26-2011 |
20110123435 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY - The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity. Formula I | 05-26-2011 |
20110123436 | Dock-and-Lock (DNL) Complexes for Delivery of Interference RNA - Described herein are compositions and methods of use of targeted delivery complexes for delivery of siRNA to a disease-associated cell, tissue or pathogen. The targeted delivery complex comprises a targeting molecule, such as an antibody or fragment thereof, conjugated to one or more siRNA carriers. In preferred embodiments the siRNA carrier is a dendrimer or protamine and the targeting molecule is an anti-cancer antibody, such as hRS7. More preferably, the antibody or fragment is rapidly internalized into the target cell to facilitate uptake of the siRNA. Most preferably, the targeted delivery complex is made by the DNL technique. The compositions and methods are of use to treat a variety of disease states, such as cancer, autoimmune disease, immune dysfunction, cardiac disease, neurologic disease, inflammatory disease or infectious disease. | 05-26-2011 |
20110129412 | Antibodies Directed to CD20 and Uses Thereof - Antibodies directed to the antigen CD20 and uses of such antibodies are disclosed herein. In particular, fully human monoclonal antibodies directed to the antigen CD20. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed. | 06-02-2011 |
20110135568 | THICKENED BEVERAGES FOR DYSPHAGIA - The present invention relates to thickened beverage compositions. More particularly the invention relates to beverage compositions thickened for the management of dysphagia. More particularly this invention relates to the production of thickened beverages by a dispensing machine that is also capable of dispensing non-thickened beverages. | 06-09-2011 |
20110150757 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY - The present invention relates to compounds of Formula (I), below, (wherein R1, R2, R3, R27, R28, R29, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity. | 06-23-2011 |
20110158901 | CHITOSAN-BASED NANOPARTICLES AND METHODS FOR MAKING AND USING THE SAME - Water-dispersible chitosan-based nanoparticles comprising a cross-linked chitosan polymer are provided. The chitosan-based nanoparticles advantageously have a particle size of about 100 nm or less and may include an imaging agent, a target-specific ligand, and/or a biologically active compound bonded to the chitosan polymer. | 06-30-2011 |
20110158902 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS - The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences. | 06-30-2011 |
20110165062 | Use of an anti-cd151 antibody for early treatment of cancer - The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the early treatment of cancer. | 07-07-2011 |
20110165063 | IL-1 BINDING PROTEINS - The present invention describes IL-1α binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1α. Binding proteins of the invention have high affinity for IL-1α and neutralize IL-1α activity. A binding protein of the invention can be a full-length antibody or an IL-1α-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1α binding proteins of the invention are useful for detecting IL-1α and for inhibiting IL-1α activity, including in a human subject suffering from a disease or disorder in which IL-1α activity is detrimental. | 07-07-2011 |
20110165064 | METHODS AND COMPOSITIONS RELATED TO CLOT-BINDING COMPOUNDS - Disclosed are compositions and methods related to clot-binding compounds. For example, disclosed are compositions comprising a surface molecule and at least one modified clot-binding compound. The modified clot-binding compound can selectively bind to clotted plasma protein, wherein the composition causes clotting and amplifies the accumulation of the composition in tumors. The modified clot-binding compound can enhance the clotting in tumors compared to its unmodified derivative. The disclosed targeting is useful for treatment of cancer and other diseases and disorders. | 07-07-2011 |
20110165065 | MEANS FOR THE DETECTION AND TREATMENT OF PROSTATE CELLS - The present invention relates to a composition for the detection and the treatment of prostate cells and to methods for the diagnostic and therapeutic treatment of a human being using the composition according to the invention. | 07-07-2011 |
20110165066 | INTERLEUKIN-13 BINDING PROTEINS - The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental. | 07-07-2011 |
20110171122 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER - A molecular probe for use in detection of cancer cells expressing an Ig superfamily cell adhesion molecule that binds in a homophilic fashion in a subject includes a targeting agent that specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of the Ig superfamily cell adhesion molecule. | 07-14-2011 |
20110171123 | In Vivo Biofilm Infection Diagnosis and Treatment - The present invention relates to a method for in vivo detection of a biofilm infection residing in a mammal, the method comprising (i) administering to the mammal a diagnostic-effective amount of a biofilm-specific probe, wherein the probe comprises a bio film-targeting moiety and a paramagnetic nanoparticle core; and (ii) imaging the mammal to detect the presence of the biofilm infection by observing the mammal using a magnetic resonance diagnostic technique after the biofilm-specific probe has been provided sufficient time to selectively bind to the bio film infection that may be present in the mammal. The invention also relates to methods of treatment of a bio film infection, and compositions and kits useful in the detection and/or treatment of bio film infections. | 07-14-2011 |
20110176993 | VEGF POLYMORPHISMS AND ANTI-ANGIOGENESIS THERAPY - Methods for determining whether a patient in at particular risk of hypertension associated with anti-VEGF treatment or has a greater likelihood of benefiting from anti-VEGF therapy by screening a sample isolated from the patient for specific genomic polymorphisms. | 07-21-2011 |
20110176994 | Buoyant Polymer Particles for Delivery of Therapeutic Agents to the Central Nervous System - The invention provides compositions and methods for treating a subject who has suffered from a central nervous system disorder. More particularly, the invention provides sustained polymeric drug delivery systems for direct delivery of therapeutic agents into the central nervous system. | 07-21-2011 |
20110182805 | Nanoparticle fabrication methods, systems, and materials - Nano-particles are molded in nano-scale molds fabricated from non-wetting, low surface energy polymeric materials. The nano-particles can include pharmaceutical compositions, taggants, contrast agents, biologic drugs, drug compositions, organic materials, and the like. The molds can be virtually any shape and less than 10 micron in cross-sectional diameter. | 07-28-2011 |
20110182806 | SYSTEMS AND METHODS FOR PARTICLE RADIATION ENHANCED DELIVERY OF THERAPY - Systems and methods for enhancing the selective targeting of agents for preferential action at a target with reduced action with healthy tissue distal the target tissue. One or more agents can be combined with nano scale structures/particles for delivery to the target tissue. Appropriate bombardment with accelerated particle radiation, such as proton radiation, induces the release of the agents at the target site. Nano carriers can be combined with therapeutic and/or imaging enhancement agents. Imaging of the target tissue can provide a verification of the delivered dose of particle radiation. Nanocarriers can be provided with an outer shell selected for biocompatibility and durability in the in vivo environment and further selected to provide a feedback mechanism in the treatment environment to accelerate the release of the agent and reduce a total radiation dose needed for that release. | 07-28-2011 |
20110182807 | Method and Dosage Form to Confirm Compliant Use of a Bioactive Agent - A dosage form includes a dose of at least one bioactive agent and a substance that can be readily confirmed by medical personnel to determine if the patient is compliant with taking the dosage form. The substance is at least one member selected from the group consisting of (a) a material incorporated in the dose in a manner that when the dosage form is properly administered is by itself or when combined with a reagent visible in the buccal, vaginal, nasal, rectal, aural, ophthalmic or ostomic cavity of a patient or an excretion of a patient in normal light or when exposed to a special frequency light source, (b) a material that is by itself not readily visible in the buccal, vaginal, nasal, rectal, aural, ophthalmic or ostomic cavity of a patient or an excretion of a patient in normal light but by itself or when combined with a reagent is readily visible when exposed to a special frequency light source, (c) a material that is by itself not readily visible in the buccal, vaginal, nasal, rectal, aural, ophthalmic or ostomic cavity of a patient or an excretion of a patient in normal light but when combined with a reagent is readily visible in normal light and (d) a material that is by itself not readily visible in the buccal, vaginal, nasal, rectal, aural, ophthalmic or ostomic cavity of a patient or an excretion of a patient in normal light but by itself or when combined with a reagent is readily detected by a non-visual detection method. | 07-28-2011 |
20110182808 | Strontium-82/Rubidium-82 Generator, Method for Producing a Rubidium-82 Comprising Diagnostic Agent, Said Diagnostic Agent and Its Use in Medicine - The invention relates to a strontium-82/rubidium-82 generator, comprising a column filled with a cationic exchanger loaded with strontium-82, and having an inlet and an outlet, and a liquid medium, wherein parts of the column, inlet and outlet coming into contact with the liquid medium are iron-free, preferably metal-free, to a method for producing rubidium-82, and to the obtained diagnostic agent. | 07-28-2011 |
20110189082 | HUMAN GM-CSF ANTIGEN BINDING PROTEINS - Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes. | 08-04-2011 |
20110189083 | Dock-and-Lock (DNL) Vaccines for Cancer Therapy - The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the DNL complex. The anti-cancer vaccine DNL complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138 | 08-04-2011 |
20110189084 | Method for Treating Liver Disorders with Receptor Associated Protein (RAP) Peptide-Fucosidase Inhibitor Conjugates - The present invention relates, in general, to methods and compositions for the treatment of liver disorders and liver tumors, such as hepatocellular carcinoma, with a peptide of the receptor associated protein (RAP) molecule conjugated to a fucosidase inhibitor. | 08-04-2011 |
20110189085 | Antibody Therapy - The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition. | 08-04-2011 |
20110195018 | LOW MOLECULAR WEIGHT THYROID STIMULATING HORMONE RECEPTOR (TSHR) AGONISTS - Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder. | 08-11-2011 |
20110200524 | VECTOR FOR USE IN MEDICINE - Provided is a vector for use in delivering a therapy to or removing a therapy from a site within a patient, wherein the vector comprises: a) a binding moiety; and b) a therapeutic agent, wherein the binding moiety comprises a metal-binding protein, polypeptide or peptide which is bound to or encapsulates a magnetic or magnetisable substance, and wherein the vector is to be administered using a device comprising an electromagnet and an element suitable for bringing the therapeutic agent into proximity with the site. | 08-18-2011 |
20110200525 | VHH ANTIBODY FRAGMENTS FOR USE IN THE DETECTION AND TREATMENT OF CANCER - The presently disclosed subject matter provides ligands for detecting and imaging cancer cells and tumors, and for guided delivery of an active agent to cancer cells and tumors. In some embodiments the ligands comprise an antibody fragment, wherein the antibody fragment comprises a VHH domain. In some embodiments a composition is provided for targeting of cancer cells or tumors. Also provided are methods for delivery of a composition to a target tissue or tumor in a subject. Also provided are methods for imaging a target tissue or tumor in a subject. In some embodiments methods for treating a tumor in a subject are provided. Also provided are methods for diagnosing a tumor in a subject. | 08-18-2011 |
20110212021 | TARGETED OLIGONUCLEOTIDE COMPOSITIONS FOR MODIFYING GENE EXPRESSION - The invention comprises compositions and methods for modifying gene expression. Modified oligos of the invention restore the lost function of let-7 wild type miRNA molecules that are prevented from silencing target genes by mutations occurring within their binding sites. Administration of a particular modified oligo (SEQ ID NO: 22) leads to increased cell death in cancer cells carrying the LCS6 SNP. | 09-01-2011 |
20110223102 | MULTIMODALITY AGENTS FOR TUMOR IMAGING AND THERAPY - A compound that is a conjugate of an antagonist to an integrin expressed by a tumor cell and at least one of a tumor avid tetrapyrollic photosensitizer, a fluorescent dye, and a radioisotope labeled moiety wherein the radioisotope is | 09-15-2011 |
20110236304 | STRUCTURAL VARIANTS OF ANTIBODIES FOR IMPROVED THERAPEUTIC CHARACTERISTICS - The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or fragments are useful for treatment of B-cell disorders, such as B-cell malignancies and autoimmune diseases, as well as GVHD, organ transplant rejection, and hemolytic anemia and cryoglobulinemia. Amino acid substitutions, particularly substitution of an aspartate residue at Kabat position 101 of CDR3 V | 09-29-2011 |
20110236305 | METHODS FOR PROTECTING AND REGENERATING BONE MARROW USING CXCR3 AGONISTS AND ANTAGONISTS - CXCR3 agonists, including natural CXCR3 ligands, promote bone marrow regeneration, increase peripheral white blood cells, and increase survival if administered prior to treatment of a subject with chemotherapy or radiotherapy. Similar effects are obtained by administering an CXCR3 antagonists following chemotherapy radiotherapy. Compositions and methods are presented for the treatment of cancer and bone marrow diseases. | 09-29-2011 |
20110250128 | Method for tissue characterization based on beta radiation and coincident Cherenkov radiation of a radiotracer - A method of characterizing a tissue sample is provided that includes injecting a tissue sample with radiotracers, where the radiotracers include beta-emitter radio tracers, the beta-emitter radio tracers emit beta particles according to a decay of the beta-emitter radio tracers, and measuring the beta particles or Cherenkov radiation from the beta particles in the tissue sample, and determining a condition of the radio tracers in the tissue sample according to the measured beta particles or the measured Cherenkov radiation, where the determined condition includes a depth and/or a concentration of the radiotracers in the tissue sample. | 10-13-2011 |
20110250129 | BIOLUMINESCENCE IMAGING-BASED SCREENING ASSAY AND INHIBITORS OF ABCG2 - A bioluminescence imaging-based high-throughput assay for inhibitors of ABCG2 is described. Compositions of inhibitors of ABCG2 and methods of using ABCG2 inhibitors are also described. | 10-13-2011 |
20110256053 | Multiple Signaling Pathways Induced by Hexavalent, Monospecific and Bispecific Antibodies for Enhanced Toxicity to B-Cell Lymphomas and Other Diseases - Disclosed herein are compositions and methods of use comprising hexavalent DNL complexes. Preferably, the complexes comprise anti-CD20 and/or anti-CD22 antibodies or fragments thereof. More preferably, the anti-CD20 antibody is veltuzumab and the anti-CD22 antibody is epratuzumab. Administration of the subject hexavalent DNL complexes induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease. In most preferred embodiments, the DNL complexes increase levels of phosphorylated p38 and PTEN, decrease levels of phosphorylated Lyn, Akt, ERK, IKKα/β and IκBα, increase expression of RKIP and Bax and decrease expression of Mcl-1, Bcl-xL, Bcl-2, and phospho-BAD in target cells. The subject DNL complexes show EC | 10-20-2011 |
20110256054 | Compositions and Methods for the Treatment and Prevention of Lens Fibrotic Diseases - Compositions and methods for treating fibrotic diseases are provided. | 10-20-2011 |
20110256055 | APPLICATION OF 99MTC PEPTIDE-BASED COMPOUND AS A BONE MARROW IMAGING AGENT - The present invention relates to methods and materials involved in using peptide-based compounds in bone marrow imaging. More specifically the invention relates to the use of 99mTc peptide-based compounds as targeting vectors that bind to receptors associated with angiogenesis, in particular integrin receptors, e.g. the αvβ3 integrin receptor. Such contrast agents may thus be used for diagnosis of haemolytic anaemia, myeloproliferative disorders, myelofibrosis, selection of biopsy sites, and early detection of skeletal metastatasis as well as detecting avascular necrosis of the femoral heads. | 10-20-2011 |
20110262347 | METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF COMPOUNDS - Disclosed are compositions and methods related to multivalent compositions targeted to cells and tissues. The disclosed targeting is useful for treatment of cancer and other diseases and disorders. | 10-27-2011 |
20110268653 | Compositions and Methods Related to Acid Stable Lipid Nanospheres - The present invention relates generally to the fields of chemistry and biochemistry. More particularly, it concerns methods and compositions for the use of fatty asparagine, fatty cysteine, and fatty serine derivatives. | 11-03-2011 |
20110268654 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET - The present application provides compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reaction for rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target. | 11-03-2011 |
20110274616 | 4-(2,6-DICHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS - The invention provides an acid addition salt of 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide and crystals thereof, the salt being formed with an acid selected from methanesulphonic acid and acetic acid and mixtures thereof. | 11-10-2011 |
20110280798 | Cell Penetrating Peptides for Intracellular Delivery - The present invention provides a cell penetrating peptide which has following sequence: NYBX | 11-17-2011 |
20110293511 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 12-01-2011 |
20110300066 | Combination Therapy With Anti-CD74 Antibodies Provides Enhanced Toxicity to Malignancies, Autoimmune Disease and Other Diseases - Disclosed herein are compositions and methods of use comprising combinations of anti-CD74 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD74 antibody or may be separately administered, either before, simultaneously with or after the anti-CD74 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD74, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80, IL-6, CXCR4 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD74 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD74 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD74 antibody and therapeutic agent that are not conjugated to each other. Administration of the anti-CD74 antibody and therapeutic agent induces apoptosis and cell death of target cells in diseases in which CD74 is overexpressed, such as solid tumors, B-cell lymphomas or leukemias, autoimmune disease, immune dysfunction disease, type 1 or type 2 diabetes. | 12-08-2011 |
20120009121 | PSMA-TARGETING COMPOUNDS AND USES THEREOF - Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described. | 01-12-2012 |
20120014868 | METHODS TO DIAGNOSE DEGENERATIVE DISC DISEASE - Methods are provided that better describe, and localize the pain generator or suspected pain generator in and around spinal discs in relation to neck or back pain so as to improve the diagnosis of degenerative disc disease. In some embodiments, there are methods for diagnosing a pain generator or a suspected pain generator in a patient suffering from back pain, the methods comprise labeling an inflammatory, vascular, neuronal, and/or metabolic pain marker at a location inside of or adjacent to an intervertebral disc in the patient suffering from back pain to increase an image of the pain marker with an imaging procedure; and imaging the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker in a manner sufficient to diagnose the pain generator or suspected pain generator. | 01-19-2012 |
20120014869 | MUC18 TARGETING PEPTIDES - Provided are MUC 18 targeting peptides which may be used, e.g., to therapeutically target B-I lymphocytes to reduce the influence of these cells on the metastatic potential of melanoma cells and/or to target cancerous cells, including certain melanoma and leukemia cells. MUC 18 targeting peptides may be comprised in fusion constructs, imaging constructs, and/or therapeutic constructs such as fusion constructs which may be used for diagnosing or treating a cancer. | 01-19-2012 |
20120020876 | HEDGEHOG PATHWAY INHIBITORS - This disclosure generally relates to methods useful for improving, for example, blood vessel density and/or blood vessel patency to a tissue by administration of a hedgehog pathway inhibitor. In certain embodiments, the hedgehog pathway inhibitor is administered with an agent to improve the delivery of the agent to the tissue. In certain embodiments, the tissue comprises tumor tissue. | 01-26-2012 |
20120020877 | PROCESS AND INTRA-CERVICAL DEVICE FOR THE LOCAL RELEASE OF DRUGS IN THE LOCAL-REGIONAL TREATMENT OF CERVICAL CANCER - An intrauterine device and more specifically an intracervical device (ICD) for the local release of drugs in the loco-regional treatment of tumours of the uterine cervix comprises an elongated stem ( | 01-26-2012 |
20120027674 | IL-18 RECEPTOR AS A NOVEL TARGET OF REGULATORY T CELLS IN CANCER - Compositions and methods for use in preventing, inhibiting or reducing tumor cell growth comprising an effective amount of an active agent that kills IL-18 Receptor expressing T cells in admixture with a suitable diluent or carrier are described herein. | 02-02-2012 |
20120034155 | Artificial cells - The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products. | 02-09-2012 |
20120034156 | Artificial cells - The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products. | 02-09-2012 |
20120039796 | Novel method for creating, suspending and stabilizing electronically modified oxygen derivatives, along with creating, suspending and stabilizing electronically modified reaction intermediates, in a bio compatible fluorocarbon suspension, for the purpose of inducing a cascading immune response in mammalian patients - A bio compatible free radical suspension, comprising of oxygen and electronically modified reaction intermediates, where a fluorocarbon is used as an inert medium for stabilization of reaction intermediates. A stabilized bio compatible electronically modified derivative suspension is produced by the subjecting a fluorocarbon to certain stressors, such as oxidizing agents, reactive intermediates, physiological gases, benzo-γ-pyrone derivatives, ultrasonic-cavitation, electric fields, magnetic fields, UV radiation, active metal catalyst, surfactant reactants, buffers, electrolytes, glucose, glucose derivatives, for the purpose of inducing a cascading immune response. | 02-16-2012 |
20120039797 | Antibody Therapy - The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition. | 02-16-2012 |
20120039798 | METHODS OF MODIFYING P53 ACETYLATION AND TREATING CANCER USING AVRA - The present invention relates to methods and compositions for the treatment of cancer. The methods and compositions involve the use of the | 02-16-2012 |
20120045389 | METHODS AND REAGENTS FOR EFFICIENT AND TARGETED GENE TRANSFER TO MONOCYTES AND MACROPHAGES - The present invention provides a biosafe and useful vector to transfer genetic material to CD14+ mononuclear cells (monocytes and monocyte-derived macrophages) in an efficient and specific manner. The embodiment of the invention makes use of the chimeric human adenovirus vectors 5 carrying the short fiber of enterotropic Ad40 to transfer genetic material to the target CD14+ mononuclear cells. | 02-23-2012 |
20120058047 | METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION - The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred embodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers. | 03-08-2012 |
20120063993 | THERAPEUTIC AND DIAGNOSTIC CONJUGATES FOR USE WITH MULTISPECIFIC ANTIBODIES - Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector molecule which may be conjugated to one or more of the haptens, the spacer/carrier, or both. The effector molecule may be conjugated by a number of linkages including an ester linkage, an imino linkage, an amino linkage, a sulfide linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage, an ether linkage, or combinations of these linkages. Also disclosed are methods of synthesizing the compounds and/or precursors of the compounds. | 03-15-2012 |
20120063994 | RTEF-1 VARIANTS AND USES THEREOF - Disclosed are variant RTEF-1 polypeptides having an RTEF-1 amino acid sequence with one or more internal deletions, wherein the polypeptides reduce VEGF promoter activity. Some of the RTEF-1 polypeptides include an amino acid sequence that is at least 80% identical to the contiguous amino acids of 1) amino acids 24 to 47 of SEQ ID NO:15 and 2) each of SEQ ID NOs:16 and 17, but does not comprise the contiguous amino acids of SEQ ID NOs:8, 9, 11, or 12. Also disclosed are nucleic acids encoding the variant RTEF-1 polypeptides of the present invention. Pharmaceutical compositions that include the polypeptides and nucleic acids of the present invention are also disclosed. Methods of inducing cell contact inhibition, regulating organ size, and reducing intracellular YAP activity are also set forth, as well as methods of treating hyperproliferative diseases such as cancer using the pharmaceutical compositions of the present invention. | 03-15-2012 |
20120063995 | NON-AD5 ADENOVIRAL VECTORS AND METHODS AND USES RELATED THERETO - Oncolytic human adenoviral vectors and cells and pharmaceutical compositions including the vectors. Also provided are methods for using the vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, methods of producing an adenoviral vector are provided. | 03-15-2012 |
20120063996 | NOVEL NIMESULIDE COMPOSITIONS - The present invention provides nanoparticulate nimesulide compositions. The compositions preferably comprise nimesulide and at least one surface stabilizer adsorbed on or associated with the surface of the nimesulide particles. The nanoparticulate nimesulide particles preferably have an effective average particle size of less than about 2000 nm. The invention also provides methods of making and using nanoparticulate nimesulide compositions. | 03-15-2012 |
20120063997 | DELIVERY SYSTEM WITH SCAFFOLDS - An injectable, agent delivery system comprising a composition comprising: (i) an injectable scaffold material comprising discrete particles, which are capable of interacting to form a scaffold; and (ii) a carrier comprising an agent for delivery. The product can have a pharmaceutical use or use in cosmetic surgery; in particular it can be used in tissue regeneration or reconstruction. The agent for delivery may be a therapeutically, prophylactically or diagnostically active substance. | 03-15-2012 |
20120063998 | Method for Treating Psoriatic Arthritis by Administering an Anti-IL-12 Antibody - Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriatic arthritis. | 03-15-2012 |
20120070368 | Methods of Using C-Met Modulators - Disclosed are methods of treating cancer by administering a compound of Formula I, | 03-22-2012 |
20120070369 | HIF INHIBITORS AND USE THEREOF - The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders. | 03-22-2012 |
20120070370 | SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS - The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity. | 03-22-2012 |
20120076722 | METHODS FOR TREATING CANCERS AND DISEASES ASSOCIATED WITH 4-1BB (CD137) EXPRESSION - The present invention relates to the role of 4-1BB (CD137) ligand and anti-4-1BB (CD137) antibody in the treatment of cancers and diseases associated with 4-1BB (CD137) expression. More particularly, the present invention relates to the use of (i) 4-1BB (CD137) ligand for inducing proliferation and activation and promoting survival of B lymphocytes and (2) anti-4-1BB (anti-CD137) antibody for inhibiting proliferation and activation and inducing death of B lymphocytes. | 03-29-2012 |
20120087857 | GADOLINIUM EXPRESSED LIPID NANOPARTICLES FOR MAGNETIC RESONANCE IMAGING - Lipid nanoparticles expressing metal ions and methods for using the compositions for magnetic resonance imaging. | 04-12-2012 |
20120087858 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 04-12-2012 |
20120087859 | NANOCARRIER HAVING ENHANCED SKIN PERMEABILITY, CELLULAR UPTAKE AND TUMOUR DELIVERY PROPERTIES - The present invention relates to a biopolymer-modified nanocarrier in which chitosan is bound to a water-soluble biocompatible polymer that has been crosslinked via a photo-crosslinkable functional group; wherein the chitosan-modified nanocarrier has a diameter which changes in accordance with changes in temperature, has enhanced skin permeability or cellular uptake and selective delivery to cancer tissue as compared with a bare nanocarrier to which chitosan has not been bound, and exhibits characteristics that are advantageous in photothermal therapy. The chitosan-modified nanocarrier of the present invention exhibits highly superior efficacy as a transdermal carrier, since the skin permeability is enhanced to a significant level as compared with a bare nanocarrier that has no chitosan. The chitosan-modified nanocarrier of the present invention can be advantageous in the imaging and photothermal therapy of tumour cells and cancer cells, since the cellular uptake by tumour cells and cancer cells is substantially improved. | 04-12-2012 |
20120093716 | USE OF ANTISECRETORY FACTORS (AF) FOR OPTIMIZING CELLULAR UPTAKE - The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition. | 04-19-2012 |
20120093717 | MICROSPHERE/NANOFIBER COMPOSITES FOR DELIVERY OF DRUGS, GROWTH FACTORS, AND OTHER AGENTS - Provided are compositions that include polymeric fibers and microspheres entrapped within the fibers, the compositions being capable of controlled delivery of one or more agents while also maintaining their structural properties. Also provided are related methods of fabricating these compositions and methods of utilizing the compositions to deliver agents to a subject. | 04-19-2012 |
20120100067 | Solubilisation Method - The present invention relates to the solubilisation of an active agent in a lipid dispersion, in particular to the solubilisation of an active agent in a suspension of preformed empty liposomes. | 04-26-2012 |
20120100068 | Anti-CD74 Immunoconjugates and Methods of Use - Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions. | 04-26-2012 |
20120107229 | NOVEL NANO-PROBES FOR MOLECULAR IMAGING AND TARGETED THERAPY OF DISEASES - The present inventions relate to compositions and methods for imaging and treating atherosclerotic diseases, pathogen infections, and tumors by administering actively targeting magnetic nanoparticles. In particular, the present inventions provide new types of targeting ligands attached to magnetic nanoparticles for magnetic resonance imaging. The use of these targeted magnetic nanoparticles is contemplated as a means to treat atherosclerotic diseases, including but not limited to inhibiting and removing atherosclerotic plaques. Further, actively targeting magnetic nanoparticles are contemplated for use with multiple labels for use in nuclear medicine imaging, computed tomography (CT) techniques and other types of imaging for medical and research applications. | 05-03-2012 |
20120107230 | Treatment of Hyperproliferative Diseases with Vinca Alkaloid N-Oxide Analogs - The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders. | 05-03-2012 |
20120107231 | METALLOPROTEINASE BINDING PROTEINS - Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described. | 05-03-2012 |
20120114554 | Engineered Aerosol Particles, And Associated Methods - An engineered aerosol particle for use in aerosol applications is provided. The engineered aerosol particle comprises a fabricated nanoparticle body member being non-spherical. The fabricated nanoparticle body member is configured to provide at least one of auto-rotation, tumbling, or lift when entrained in an airstream to thereby increase settling time of the fabricated nanoparticle body member. An associated method is also provided. | 05-10-2012 |
20120121501 | HMGN2 PEPTIDES AND RELATED MOLECULES THAT SELECTIVELY HOME TO TUMOR BLOOD VESSELS AND TUMOR CELLS - The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided. | 05-17-2012 |
20120121502 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF - The present invention relates to novel pyrimidine hydroxy amide compounds, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6. | 05-17-2012 |
20120128580 | PRESELECTION OF SUBJECTS FOR THERAPEUTIC TREATMENT WITH ELESCLOMOL BASED ON HYPOXIC STATUS - The present invention provides methods for the preselection of a subject for therapeutic treatment with elesclomol based on modulated levels of hypoxia in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with elesclomol based on modulated levels of lactate dehydrogenase (LDH). The invention also provides methods for treating cancer in a subject by administering an effective amount of elesclomol to the subject, wherein the subject has a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention. | 05-24-2012 |
20120128581 | Sincalide Formulations - The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations as well as methods for treating, preventing, and diagnosing gall bladder-related disorders using sincalide formulations. | 05-24-2012 |
20120134917 | DERMATOLOGICAL COMPOSITION - Dermatological methods of cosmetic, therapeutic, prophylactic, and/or diagnostic treatment by topically applying compositions comprising a multiplicity of particles, at least one of the particles comprising porous and/or polycrystalline silicon. Included are methods and compositions for sun protection applications. The use of porous silicon, polycrystalline silicon, and porous silicon oxide mirrors is disclosed. | 05-31-2012 |
20120148488 | Targeting Kidney Mesangium With Nanoparticles of Defined Diameter - Described herein are methods of treating a disorder affecting the mesangial cells in a subject by administering an engineered nanoparticle (ENP) capable of delivering a therapeutic agent to the subject. Also provided are diagnostic methods for administering to a subject an ENP, analyzing a mesangial cell of the subject and determining whether the engineered nanoparticle is present in a mesangial cell of the subject. | 06-14-2012 |
20120148489 | Targeting Kidney Mesangium With Nanoparticles of Defined Diameter - Described herein are methods of treating a disorder affecting the mesangial cells in a subject by administering an engineered nanoparticle (ENP) capable of delivering a therapeutic agent to the subject. Also provided are diagnostic methods for administering to a subject an ENP, analyzing a mesangial cell of the subject and determining whether the engineered nanoparticle is present in a mesangial cell of the subject. | 06-14-2012 |
20120156128 | CONTROLLABLE RELEASE COMPOSITION AND METHOD FOR PREPARING SAME - A controllable release composition is provided, including a polymer substrate and an active ingredient, in which the polymer substrate is a polymer blend including a biodegradable polyester, polyanhydride, and/or polyether, and the active ingredient includes a radioactive agent or a chemotherapeutic agent. The controllable release composition is useful for cancer therapy, particularly for solid cancer treatment. | 06-21-2012 |
20120171114 | ANTI-CD151 ANTIBODIES AND THEIR USE IN THE TREATMENT OF CANCER - The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers. | 07-05-2012 |
20120177566 | MEMBRANE RESIDENT PEPTIDE IN ANTI-CANCER PEPTIDES CAUSES TUMOR CELL NECROSIS RATHER THAN APOPTOSIS OF CANCER CELLS - An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form. | 07-12-2012 |
20120177567 | Methods of Treating Pediatric Acute Lymphoblastic Leukemia with an Anti-CD22 Immunotoxin - The present invention provides methods for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients using an anti-CD22 immunotoxin. The methods disclosed comprise administering to a pediatric patient in need of that treatment an effective dose of a recombinant immunotoxin comprising a variable light (V | 07-12-2012 |
20120183471 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 07-19-2012 |
20120189537 | NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS - Disclosed are nitrile derivatives and pharmaceutical compositions comprising nitrile derivatives. The pharmaceutical compositions comprise compounds of the formula I | 07-26-2012 |
20120189538 | USE OF A2A ADENOSINE RECEPTOR AGONISTS - Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A | 07-26-2012 |
20120189539 | BCL-2/BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME - Inhibitors of Bcl-2/Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2/Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2/Bcl-xL provides a benefit, like cancers, also are disclosed. | 07-26-2012 |
20120189540 | IL3Ralpha Antibody Conjugates And Uses Thereof - The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα. | 07-26-2012 |
20120195826 | INJECTABLE BIOMATERIAL - The invention relates to an injectable biomaterial. The injectable biomaterial of the invention comprises a non aqueous solvent which is compatible for injection to human being and nanoparticles made of a polymer which is insoluble in water and insoluble in said non aqueous solvent, said nanoparticles being loaded with a drug or a biological agent. The injectable biomaterial of the invention is particularly appropriate for occluding normal or malformative blood vessels or non circulating cavities or for necrosing tumors. | 08-02-2012 |
20120195827 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS - A myocardial imaging method that is accomplished by administering one or more adenosine A | 08-02-2012 |
20120195828 | KIDNEY-IMAGING AGENT COMPRISING RECOMBINANT GELATIN - An object of the present invention is to provide a kidney-imaging agent which is composed of bioabsorbable materials, transiently accumulates in a kidney for a short period of time, and does not remain in the kidney for a prolonged time after accumulation. The present invention provides a kidney-imaging agent which comprises a gelatin-like protein. | 08-02-2012 |
20120201746 | HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF - The invention provides compositions, methods, and kits related to half-Ig binding proteins that include a functional antibody binding site and a CH3 domain wherein the CH3 domain includes at least one mutation to inhibit CH3-CH3 dimerization. | 08-09-2012 |
20120201747 | System and Method for Diagnosis and Treatment - This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment. | 08-09-2012 |
20120201748 | COACERVATE HAVING AN IONIC POLYMER MIXED WITH THE ADHESIVE PROTEIN OF A MUSSEL OR OF A SPECIES OF THE VARIOME THEREOF - The present invention relates to a coacervate comprising a mussel adhesive protein and an anionic polymer, and more particularly, to a coacervate prepared by mixing a mussel adhesive protein with an anionic polymer, and a novel use thereof. In the present invention, a coacervate prepared by mixing a mussel adhesive protein and an anionic polymer shows a very excellent adhesive strength to various substrates such as cells or metals, and is able to maintain its adhesive strength in the presence of water or under water, thereby being effectively used as an adhesive. Moreover, it has an activity capable of encapsulating bioactive materials, thereby being effectively used as an active component of a composition for delivering bioactive materials. | 08-09-2012 |
20120201749 | NP-1 Antagonists and Their Therapeutic Use - Compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein: W is arylene, heteroarylene or formula (a) each L is independently alkylene, alkenylene, alkynylene, a direct bond, arylene, cycloalkylene, alkylene-arylene, alkylene-C═O or —C═O; each X is independently an N-containing heteroarylene, N-containing cycloalkylene or NR; Y is N-containing heteroaryl, N-containing cycloalkyl, NR | 08-09-2012 |
20120207670 | Method for Treating Psoriasis by Administering An Anti-IL-12 Antibody - An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in treating IL-12-related disorders, such as psoriasis. | 08-16-2012 |
20120207671 | COMBINATION TREATMENT WITH VEGF-C ANTAGONISTS - The invention relates to a method and kit for treating cancer in a human subject, the method comprising administering to the subject in combination therapeutically effective amounts of a VEGF-C antagonist and an anti-neoplastic composition, and the kit comprising a VEGF-C antagonist for administering to the subject in combination with an anti-neoplastic composition. The invention further relates to methods for: increasing the duration of survival of, increasing the progression-free survival of, increasing the duration of response of, or treating, a subject or a group of human subjects susceptible to or diagnosed as having a cancer; or treating a human subject or a group of human subjects having metastatic colorectal cancer, prostate cancer, pancreatic cancer or glioblastoma, the methods comprising administering to the subject or subjects in the group in combination effective amounts of a VEGF-C antagonist and an anti-neoplastic composition. | 08-16-2012 |
20120225011 | Glassy compositions - Embodiments disclosed herein relate to thermostable storage of one or more therapeutic agents, including at least one detectable indicator. In an embodiment, the one or more therapeutic agents including at least one detectable indicator are included in at least one glassy substance. Also disclosed are embodiments relating to delivery devices for administration of the thermostable therapeutic agents. | 09-06-2012 |
20120225012 | COMPOSITION FOR HARD TISSUE REPAIR - The composition for hard tissue repair of the present invention is characterized by comprising 5 to 98.95 parts by weight of a monomer (A), 1 to 75 parts by weight of a (meth)acrylate polymer (B) and 0.05 to 20 parts by weight of a polymerization initiator composition (C) containing an organoboron compound (c1), with the proviso that the total amount of the components (A), (B) and (C) is 100 parts by weight. The composition undergoes small-scale heat generation during curing and can ensure a sufficient working time. | 09-06-2012 |
20120237441 | ENHANCED B CELL CYTOTOXICITY OF CDIM BINDING ANTIBODY - Formulations and methods of treating human patients suffering from a condition characterized by lymphoid cancer, autoimmune disease or B cell hyperproliferation are disclosed, the treatment comprising administering (1) a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell, and (2) a cytotoxic agent, including a chemotherapeutic agent, radioactive isotope, cytotoxic antibody, immunoconjugate, ligand conjugate, immunosuppressant, cell growth regulator and/or inhibitor, toxin, or mixtures thereof, including agents that disrupt the cytoskeleton of B cells, particularly vinca alkaloids or colchicine. | 09-20-2012 |
20120244067 | METHODS FOR INDUCING REVERSIBLE STASIS - The present invention concerns compositions and methods involving incubating biological materials under hypoxic or anoxic conditions to induce stasis or suspended animation. Methods of screening for compounds that induce stasis or compounds that increase the ability to undergo stasis are included. Such methods have ramifications for preserving biological materials as well as reducing or preventing trauma to biological materials. Also contemplated are methods for screening compounds that are active or more active under hypoxic conditions than normoxic conditions. Such methods can be used to identify antitumor compounds that would operate under hypoxic conditions in which tumor cells survive. | 09-27-2012 |
20120244068 | Microorganisms for imaging and/or treatment of tumors - Modified viruses encoding transporter proteins and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses also can be used in diagnostic methods, such detection and imaging of tumors. The viruses also can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. | 09-27-2012 |
20120251439 | Antigens Associated with Inflammatory Bowel Disease Including Ulcerative Colitis - Specific binding members that bind the ED-A isoform of fibronectin for use in methods of diagnosis, detection, imaging and/or treatment of inflammatory bowel disease such as ulcerative colitis and/or for use in delivery to the neovasculature of intestinal tissue of a molecule conjugated to the specific binding member. Specific binding members that bind tenascin-C, especially the A1, A2, A3, A4 and/or D domain tenascin-C large isoform, for use in methods of diagnosis, detection, imaging and/or treatment of ulcerative colitis and/or for use in delivery to the neovasculature of inflammatory bowel disease tissue of a molecule conjugated to the specific binding member. | 10-04-2012 |
20120251440 | METHODS OF MYOCARDIAL PERFUSION IMAGING - The present invention provides a method for identifying and using partial adenosine A | 10-04-2012 |
20120258038 | USES OF APOPTOTIC CELL-TARGETING PEPTIDES, LABEL SUBSTANCES AND LIPOSOMES CONTAINING A THERAPEUTIC AGENT FOR PREVENTING, TREATING OR THERAPEUTICALLY DIAGNOSING APOPTOSIS-RELATED DISEASES - The present invention relates to a composition for preventing, treating or theranosis of apoptosis-related diseases comprising liposome comprising apoptotic cell-targeting peptides, label substances and a therapeutic agent. The present invention may be used for drug delivery to the apoptotic cells in cancer or tumor mass, the apoptotic myocardial cells in myocardial infarction lesion, the apoptotic stroke cells in stroke lesion, the apoptotic cells in arteriosclerosis lesion and further may be used for detection of the cells and imaging diagnosis. Therefore, it can be used for theranosis as well as preventing or treating the diseases. | 10-11-2012 |
20120263643 | BRACHYTHERAPY SEED - A radiopaque brachytherapy seed for implantation into a subject includes a biocompatible component, a therapeutically active component including a non-radioactive drug, and a radiopaque marker. The biocompatible component is (a) physically associated with a therapeutically active component and (b) in contact with the radiopaque marker. The brachytherapy seed has a size and shape suitable for passing through the bore of a needle having an interior diameter of less than about 2.7 millimeters (10 gauge). | 10-18-2012 |
20120269720 | DETECTION OF HEPATIC INSULIN RESISTANCE - Disclosed are methods for determining whether a subject may have hepatic insulin resistance, for diagnosing hepatic insulin resistance, and for assessing the prognosis of a subject with hepatic insulin resistance, comprising determining the level of expression of major facilitator superfamily domain 2 protein (Mfsd2) in a subject's liver, where overexpression of Mfsd2 is indicative of hepatic insulin resistance. | 10-25-2012 |
20120269721 | TARGETED NANOCLUSTERS AND METHODS OF THEIR USE - This invention provides targeted nanoclusters comprising multiple polyvalent nanoparticle core units or nanoscaffolds, each nanoparticle core unit attached to multiple targeting moieties and multiple detectable moieties. The nanoclusters find use in a broad range of analytical assays, diagnostic assays and as targeted therapeutics. | 10-25-2012 |
20120275996 | IL-1 Binding Proteins - The present invention describes IL-1α binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1α. Binding proteins of the invention have high affinity for IL-1α and neutralize IL-1α activity. A binding protein of the invention can be a full-length antibody or an IL-1α-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1α binding proteins of the invention are useful for detecting IL-1α and for inhibiting IL-1α activity, including in a human subject suffering from a disease or disorder in which IL-1α activity is detrimental. | 11-01-2012 |
20120275997 | CHIMERIC ANTIBODIES SPECIFIC FOR CD151 AND USE THEREOF IN THE TREATMENT OF CANCER - The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those anitbodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers. | 11-01-2012 |
20120275998 | BIODEGRADABLE STENT COMPRISING AN ACID SCAVENGING AGENT - A biodegradable stent comprising a biodegradable material having dissolved therein an acid scavenging agent. The biodegradable material may be PLLA or PLGA. The acid scavenging agent may be also a pharmaceutical agent, for example an antiproliferative agent, coronary vasodilator agent and/or a bronchodilator. Preferably the acid scavenging agent is dipyridamole and/or mopidamol. The invention also provides a method of preparing a biodegradable material for use in the stent of the invention comprising: (i) preparing a formulation of the biodegradable material and the acid scavenging agent; (ii) heating the formulation to melt the biodegradable material and the acid scavenging agent so as to dissolve the agent in the material; and (iii) collecting and cooling the formulation of step (ii). | 11-01-2012 |
20120275999 | ONCOLYTIC RHABDOVIRUS - Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo. | 11-01-2012 |
20120282167 | METHOD FOR PREDICTING THE SENSITIVITY OF A TUMOR TO AN EPIGENETIC TREATMENT - The present invention provides a method for determining the RES phenotype in a tumor. The present invention further provides a method for predicting the sensitivity of a tumor to an epigenetic treatment, the method comprising determining the RES phenotype in said tumor, the presence of the RES phenotype in a tumor being indicative of a tumor sensitive to an epigenetic therapy. The present invention also provides a method for diagnosing an aggressive tumor and for selecting a patient affected with a tumor for an epigenetic therapy. | 11-08-2012 |
20120282168 | METHODS OF SENSITIZING CANCER TO THERAPY-INDUCED CYTOTOXICITY - The present application demonstrates that Salinosporamide A can be used to sensitize cancer cells to cancer therapy. Furthermore, the present application demonstrates that Salinosporamide A acts as a therapeutic agent to kill or inhibit cancer cells after sensitization of the cells by an antibody or other chemosensitizing reagents. The cancer cells can be either therapy-sensitive or therapy resistant. The present application further demonstrates that Salinosporamide A induces the expression of Raf kinase inhibitor protein (RKIP) and PTEN, tumor suppressor proteins, and inhibits the expression of YY1, a transcriptional regulator protein overexpressed in cancer cells and also inhibits the growth factor pleiotrophin (PTN). | 11-08-2012 |
20120282169 | DETECTION AND TREATMENT OF TRAUMATIC BRAIN INJURY - The present invention relates to the detection of traumatic brain injury by detecting Aβ protein aggregates associated with traumatic brain injury. These Aβ protein aggregates are detected using peptide and peptide mimic probes that preferentially associate with Aβ protein aggregates associated with traumatic brain injury. | 11-08-2012 |
20120282170 | ANTI- TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods. | 11-08-2012 |
20120288441 | INJECTABLE BIODEGRADABLE PARTICLES - According to an aspect of the invention, injectable polymeric particles are provided that contain a copolymer that contains a hydroxy-acid-based repeat unit selected from a mono(hydroxy acid) unit and a poly(hydroxy acid) unit, an alkyl-ether-based repeat unit selected from a mono(alkyl ether) unit and a poly(alkyl ether) unit, and an acid-based repeat unit selected from a unit comprising multiple carboxylic acid groups and a derivative thereof. Other aspects of the invention pertain to methods of making such particles. Still other aspects of the invention pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions. | 11-15-2012 |
20120294796 | Antibodies Reactive with B7-H3 and Uses Thereof - The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers. | 11-22-2012 |
20120294797 | ANTI-CGRP COMPOSITIONS AND USE THEREOF - The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 11-22-2012 |
20120301393 | MODIFIED UBIQUITIN PROTEINS HAVING A SPECIFIC BINDING ACTIVITY FOR THE EXTRADOMAIN B OF FIBRONECTIN - The present invention refers to novel recombinant proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B). Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component. | 11-29-2012 |
20120321552 | Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin - Screening and diagnostic reagents, kits and methods for primary and/or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach or esophageal cancer are disclosed. | 12-20-2012 |
20120321553 | Ultrafiltration Concentration of Allotype Selected Antibodies for Small-Volume Administration - Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies. | 12-20-2012 |
20120321554 | PLEXIN D1 AS A TARGET FOR TUMOR DIAGNOSIS AND THERAPY - The present invention relates to plexin D1 for use as a targetable protein in the treatment or diagnosis of disorders that involve expression of plexin D1. Diagnosis is suitably effected by detecting the presence of plexin D1 in the body or a bodily tissue or fluid, whereas treatment is effected by targeting plexin D1 for delivery of therapeutics to the site where treatment is needed. The invention further relates to the use of molecules that bind plexin D1, a nucleic acid encoding plexine D1 or a ligand of plexin D1 for the preparation of a therapeutical composition for the treatment or diagnosis of disorders that involve expression of plexin D1. The disorders comprise disorders in which plexin D1 is expressed on tumor cells, tumor blood vessels or activated macrophages. | 12-20-2012 |
20120328511 | Novel Antigen Binding Proteins - Antigen binding proteins, such as antibodies, that interact with Epidermal Growth Factor Receptor (EGFR) are described. Methods of treating cancers and other diseases by administering a pharmaceutically effective amount of an antigen binding protein to EGFR are also described. | 12-27-2012 |
20120328512 | Fibrin-Binding Peptides and Conjugates Thereof - Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging, etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof. | 12-27-2012 |
20130004414 | DEVICES AND METHODS FOR REDUCING RADIOLYSIS OF RADIOISOTOPES - Disclosed are microfluidic devices and kits for containing radioisotopes. The devices and kits comprises at least one confining geometry having a cross-section dimension below the beta(+) or beta(−) range of a radioisotope, when containing the radioisotope configured in such a way that that neighboring segments of the confining geometries are isolated from its nearest neighbor such that no measurable kinetic positron energy transfer occurs between the segments when containing the radioisotope. Methods of storage and synthesis of radiopharmaceuticals are also disclosed. In another aspect, the present invention relates to methods of storing radiotracers and synthesizing radiopharmaceuticals, using the aforementioned device. The radiotracers and radiopharmaceuticals comprises | 01-03-2013 |
20130004415 | Joint-Homing Peptides and Uses Thereof - The present invention provides peptides that home to a joint of an animal, wherein said peptide comprises an amino acid motif selected from the group consisting of NQR and ADK. Also provided are methods of treating a subject having an arthritic joint, comprising the step of administering to said subject a pharmacologically effective dose of a composition provided herein. | 01-03-2013 |
20130004416 | Dual Variable Domain Immunoglobulin and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 01-03-2013 |
20130011332 | Frozen Compositions and Methods for Piercing a Substrate - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 01-10-2013 |
20130017147 | TARGETING AGENT FOR TUMOR SITEAANM Ogiwara; KazutakaAACI Ashigarakami-gunAACO JPAAGP Ogiwara; Kazutaka Ashigarakami-gun JPAANM Ohno; MakotoAACI Ashigarakami-gunAACO JPAAGP Ohno; Makoto Ashigarakami-gun JPAANM Kojima; MasayoshiAACI Ashigarakami-gunAACO JPAAGP Kojima; Masayoshi Ashigarakami-gun JPAANM Kawakami; MasayukiAACI Ashigarakami-gunAACO JPAAGP Kawakami; Masayuki Ashigarakami-gun JPAANM Kakinuma; ChihayaAACI Ashigarakami-gunAACO JPAAGP Kakinuma; Chihaya Ashigarakami-gun JPAANM Sasaki; TasukuAACI Ashigarakami-gunAACO JPAAGP Sasaki; Tasuku Ashigarakami-gun JPAANM Takada; KiyohitoAACI Ashigarakami-gunAACO JPAAGP Takada; Kiyohito Ashigarakami-gun JP - It is an object of the present invention to provide a targeting agent, which enables the delivery of a drug to tumor sites or the imaging of tumor sites by utilizing its effect of accumulating to such tumor sites. The present invention provides a targeting agent for tumor site, which comprises a hydrophilic polymer-modified carrier coated with a gelatin-like protein that has repeats of a sequence represented by Gly-X—Y characteristic to collagen and has two or more sequences of cell adhesion signals in a single molecule wherein X and Y each independently represent an amino acid and a plurality of Gly-X—Y sequences may be the same or different. | 01-17-2013 |
20130017148 | SYSTEMS FOR PRODUCING MULTILAYERED PARTICLES, FIBERS AND SPRAYS AND METHODS FOR ADMINISTERING THE SAME - Capsules and particles with at least one encapsulated and/or entrapped agent, such as therapeutic agent, imaging agents, and other constituents may be produced by electrohydrodynamic processes. More particularly, the agent encapsulated in a vehicle, capsule, particle, vector, or carrier may maximize treatment and/or imaging of malignant cancers while minimizing the adverse effects of treatment and/or imaging. | 01-17-2013 |
20130022538 | APTAMER-MRNA CONJUGATES FOR TARGETED PROTEIN OR PEPTIDE EXPRESSION AND METHODS FOR THEIR USE - An aptamer-mRNA conjugate is provided. The aptamer-mRNA conjugate may include an aptamer component that binds a membrane associated protein on a target cell and an mRNA component that is expressed by the target cell. | 01-24-2013 |
20130028835 | METHOD FOR GENERATING ACTIVE ANTIBODIES AGAINST A RESISTANCE ANTIGEN, ANTIBODIES OBTAINED BY SAID METHOD AND THEIR USES - The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer. | 01-31-2013 |
20130034492 | Class I Anti-CEA Antibodies and Uses Thereof - The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer. | 02-07-2013 |
20130039847 | LIPOSOMES FOR PULMONARY ADMINISTRATION - The invention relates to liposomes for pulmonary application, advantageously comprising at least one first and at least one second phospholipid, cholesterol, and at least one active substance and/or colorant, wherein the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably selected from the group DMPC, DPPC, DPPE. It is thereby advantageous if the first and the second phospholipid are present at a molar ratio of 0.5:1 to 10:1, preferably at a ratio of 6:1 to 2:1, in particular preferably at a ratio of 3:1. It is further advantageous if the molar ratio between phospholipids and cholesterol is between 10:1 and 1:1, preferably between 6:1 and 3:1, in particular preferably 4:1. The second phospholipid is further preferably DMPC or DPPE, in particular preferably DPPE. The size of the liposomes is advantageously between 0.05 μm and 5 μm, preferably between 0.2 μm and 2.0 μm, and the median aerodynamic mass diameter of aerosol particles comprising the liposomes is between 1 μm and 6 μm, preferably between 1.5 μm and 5 μm, in particular preferably between 2 μm and 4.5 μm. It is further in particular advantageous if the liposomes comprise an atomization stability of greater than 50%, preferably greater than 75%, in particular preferably greater than 80%, and if the transition temperature is greater than 37° C., preferably greater than 45° C., in particular preferably greater than 50° C. | 02-14-2013 |
20130045160 | Magnetic Nano-Composite for Contrast Agent, Intelligent Contrast Agent, Drug Delivery Agent for Simultaneous Diagnosis and Treatment, and Separation Agent for Target Substance - The present invention relates to water soluble magnetic nanocomposite using an amphiphilic compound. Specifically, the present invention relates to water soluble magnetic nanocomposite which may be not only used as a contrast agent for magnetic resonance imaging (MRI), an intelligent contrast agent for diagnosing cancer characterized by binding a tissue-specific binder ingredient, a drug delivery system for simultaneous diagnosis and treatment by polymerizing or enveloping drugs and binding a tissue-specific binder ingredient, but also used for separating a target substance using magnetism, and a process for preparing the same. | 02-21-2013 |
20130064759 | COPOLYMER-STABILIZED EMULSIONS - An emulsion includes a substantially continuous liquid medium, and a plurality of droplet structures dispersed within the substantially continuous liquid medium. Each droplet structure of the plurality of droplet structures includes an outer droplet of a first liquid having an outer surface; an inner droplet of a second liquid within the first droplet, the second liquid being immiscible in the first liquid, wherein the inner and outer droplets have a boundary surface region therebetween; an outer layer of block copolymers disposed on the outer surface of the outer droplet; and an inner layer of block copolymers disposed on the boundary surface region between the outer and the inner droplets. | 03-14-2013 |
20130064760 | Method for Treating Crohn's Disease By Administering An Anti-IL-12 Antibody - Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as Crohn's disease. | 03-14-2013 |
20130071319 | Compositions and Methods for Surface Abrasion with Frozen Particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 03-21-2013 |
20130071320 | IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES WHICH TARGET B-CELLS - Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies. | 03-21-2013 |
20130084241 | DEVELOPMENT OF miRNA DIAGNOSTICS TOOLS IN BLADDER CANCER - The present invention includes methods and compositions related to diagnosis of bladder cancer, including the presence of bladder cancer and/or the type or stage of bladder cancer. In specific embodiments, the expression of one, two, three, four, five, or more miRNAs of the invention are associated with detection of bladder cancer, typing of bladder cancer, or staging of bladder cancer. Kits and microarrays are encompassed in the invention. | 04-04-2013 |
20130089495 | METHOD FOR SCREENING SIZE OF CARRIER - The present invention provides a method for screening the size of carrier for a subject in need, comprising: (a) providing a series of labeled carriers which have different sizes; (b) administering one of the series of carriers to a subject who suffers from an organ dysfunction; (c) monitoring biodistribution of the carrier of step (b) in said subject; (d) repeating steps (b) and (c) until all the series of carriers are administered and all the biodistribution of the series of carriers are monitored; and (e) determining the size of carrier for said subject in accordance with the retention time of the series of carriers in the dysfunctional organ of said subject. The method can be used as a screening platform for drug carrier, in which the optimal size of carrier can be screened for the dysfunctional organ of the subject. | 04-11-2013 |
20130095031 | ISOTOPE PRODUCTION METHOD - The present invention relates to a method for the generation of | 04-18-2013 |
20130121912 | MICRORNA-198 AS A TUMOR SUPPRESSOR IN PANCREATIC CANCER - A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, MiR-198 replacement reverses tumorigenicity in vitro and in vivo. embodiment of the disclosure is a method of treating cancer in an individual, comprising the step of increasing the level of active microRNA-198 molecules in the pancreatic cancer tumor cells of the individual by an amount sufficient to cause an improvement in the pancreatic cancer in the individual. | 05-16-2013 |
20130129614 | Microorganisms for imaging and/or treatment of tumors - Modified viruses encoding transporter proteins and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses also can be used in diagnostic methods, such detection and imaging of tumors. The viruses also can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. | 05-23-2013 |
20130129615 | METHODS, COMPOSITIONS AND KITS FOR PROVIDING A THERAPEUTIC TREATMENT - The present invention encompasses a therapeutic method which employs treatment of a disease such as cancer with triiodothyronine (T3) together with an anti-thyroid treatment such as treatment with an anti-thyroid agent, treatment with radioiodine and surgical removal of all or part of the thyroid gland. A pharmaceutical composition comprising T3 and an anti-thyroid agent and a kit comprising the same are also encompassed by the invention. | 05-23-2013 |
20130129616 | GEL COMPOSITION FOR FILLING A BREAST MILK DUCT PRIOR TO SURGICAL EXCISION OF THE DUCT OR OTHER BREAST TISSUE - The invention is a gel composition for delivery to a breast milk duct prior to surgical excision of breast tissue including cancerous lesions. The invention also provides methods of mapping all or nearly all of a breast milk duct prior to surgical excision of breast tissue, and method of identifying part or all of a breast duct or ducts as a surgical aide to a breast surgeon. Kits to support these methods and including these compositions are also provided. | 05-23-2013 |
20130129617 | Method for Treating Psoriatic Arthritis By Administering An Anti-IL-12 Antibody - An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in treating IL-12-related disorders, such as psoriatic arthritis. | 05-23-2013 |
20130142728 | MIRNAS AS DIAGNOSTIC BIOMARKERS TO DISTINGUISH BENIGN FROM MALIGNANT THYROID TUMORS - Embodiments concern methods and compositions for distinguishing benign from malignant thyroid tumors in a patient based on the expression levels of one or more miRNAs. | 06-06-2013 |
20130149236 | Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof - The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers. | 06-13-2013 |
20130156691 | Antibody Therapy - The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition. | 06-20-2013 |
20130156692 | VEGF-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING - The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents. | 06-20-2013 |
20130171059 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Multivalent and multispecific binding proteins, methods of making, and their uses in the diagnosis, prevention, and/or treatment diseases are provided. | 07-04-2013 |
20130171060 | UP AND DOWN CONVERSION SYSTEMS FOR PRODUCTION OF EMITTED LIGHT FROM VARIOUS ENERGY SOURCES - A system for energy upconversion and/or down conversion and a system for producing a photostimulated reaction in a medium. These systems include 1) a nanoparticle configured, upon exposure to a first wavelength λ | 07-04-2013 |
20130177498 | METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY AND DETECTION OF INFLAMMATORY AND IMMUNE-DYSREGULATORY DISEASE, INFECTIOUS DISEASE, PATHOLOGIC ANGIOGENESIS AND CANCER - Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include proinflammatory effectors of the innate immune system and targets specifically associated with an inflammatory or immune-dysregulatory disorder, wherein the targets included in the latter group are not a proinflammatory effector of the immune system. Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system. The multispecific antagonists are used in the treatment of various diseases that are generated or exacerbated by, or otherwise involve, proinflammatory effectors of the innate immune system. | 07-11-2013 |
20130195751 | SELF-ASSEMBED CONJUGATE AND USE THEREOF - Provided are a self-assembled conjugate of a host molecule containing compound and a guest molecule containing compound, a delivery composition of a bioactive material comprising the self-assembled conjugate and a bioactive material to be delivered, and a composition for tissue engineering containing the self-assembled conjugate and a cell. | 08-01-2013 |
20130195752 | FUNCTIONALIZED NANOPARTICLES AND METHODS OF USE THEREOF - Certain embodiments of the present invention provide functionalized nanoparticles and methods of use thereof. Certain embodiments provide nanoparticles functionalized with streptokinase. Certain embodiments of the present invention provide methods for treating a pathological fibrin associated disorder (e.g., cancer) in an animal. | 08-01-2013 |
20130195753 | Temporary Embolization Using Inverse Thermosensitive Polymers - One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter, and which compositions gel at or below body temperature. In certain embodiments of the methods of embolization, said composition further comprises a marker molecule, such as a dye, radiopaque, or an MRI-visible compound. | 08-01-2013 |
20130195754 | IL-l BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 08-01-2013 |
20130202525 | MULTIFUNCTIONAL NANOPLATFORMS FOR FLUORESCENCE IMAGING AND PHOTODYNAMIC THERAPY DEVELOPED BY POST-LOADING PHOTOSENSITIZER AND FLUOROPHORE TO POLYACRYLAMIDE NANOPARTICLES - A composition comprising PAA nanoparticles containing a post loaded tetrapyrollic photosensitizer and a postloaded imaging agent and methods for making and using same. | 08-08-2013 |
20130224107 | HETEROCYCLIC DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF - Disclosed are heterocyclic derivatives, methods for making them, compositions containing the same and uses thereof. Particularly, their pharmaceutical use as inhibitors of PARP is disclosed. | 08-29-2013 |
20130230452 | CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ("PNAs") WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER - A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2′-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50. | 09-05-2013 |
20130230453 | DIAGNOSIS AND TREATMENT OF BRAIN TUMORS - The present invention relates to methods for the localisation, diagnosis, prognosis and/or prediction of therapeutic outcome of cancer, as well as methods for treating or preventing cancer. In particular, the present invention relates to methods for the localisation, diagnosis, prognosis and/or prediction of therapeutic outcome of brain tumors expressing calcitonin receptor, as well as the treatment and prevention of brain tumors by targeting calcitonin receptor expressing brain tumour cells. | 09-05-2013 |
20130230454 | Therapeutic Angiogenesis for Treatment of the Spine and Other Tissues - Methods for the diagnosis and treatment of ischemic spinal conditions, degenerative disc disease, back pain and/or other tissue pathologies. Patients with ischemic spine disease can be categorized into subsets that are deemed to have potential to respond to therapy. In particular, therapies are disclosed which involve stimulation of neovascularization so as to increase perfusion of spinal and other anatomies. | 09-05-2013 |
20130230455 | USE OF GELSOLIN TO TREAT MULTIPLE SCLEROSIS AND TO DIAGNOSE NEUROLOGIC DISEASES - The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases. | 09-05-2013 |
20130251628 | LIGANDS TO RADIATION-INDUCED MOLECULES - A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. In some embodiments, the method includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are targeting ligands that bind an irradiated tumor and therapeutic and diagnostic methods that employ the disclosed targeting ligands. | 09-26-2013 |
20130251629 | NANOEMULSION FOR THE DELIVERY OF AT LEAST TWO AGENTS OF INTEREST - The present invention relates to a nanoemulsion in gel-form comprising a continuous aqueous phase and at least one dispersed oily phase, in which: | 09-26-2013 |
20130259799 | HUMAN GM-CSF ANTIGEN BINDING PROTEINS - Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes. | 10-03-2013 |
20130259800 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT - The invention described herein pertains to the use of oxazolidinone antibiotics, alone or in combination, in the treatment of cancer. In particular, the invention pertains to the treatment of malignant gliomas, thyroid cancer or melanoma, or borderline forms of malignant glioma, thyroid cancer or melanoma. | 10-03-2013 |
20130266508 | THERMOSENSITIVE HYDROGEL FOR COATING RADIOISOTOPE AND CHEMOTHERAPEUTIC AGENT TO TREAT CANCER AND METHOD FOR PREPARING THE SAME - A thermosensitive hydrogel for coating radioisotopes and chemotherapeutic agents to treat cancer and a method for preparing the same are revealed. The anticancer drugs such as radiopharmaceuticals or chemotherapeutic agents are coated with the hydrogel formed by PCL-PEG-PCL. By the feature of the hydrogel body that changes from liquid phase at low storage temperature to gel form at body temperature, not only the anticancer drugs can be injected into the human body and reaching the treatment site smoothly but the treatment time of brachytherapy is also extended. Thus the side effects of cancer therapy are significantly reduced. | 10-10-2013 |
20130280162 | uPAR-ANTAGONISTS AND USES THEREOF - The invention relates to inhibitors of the urokinase-type plasminogen activator receptor (uPAR). The generated inhibitors are bivalent uPAR-ligands containing the receptor binding domains of the extracellular protease urokinase-type plasminogen activator (uPA) and of the extracellular matrix protein vitronectin (VN), in different configurations, linked by a scaffold. The present invention also refers to the above molecules for use as a medicament, in particular for treatment of cancer, and for diagnostic purposes. | 10-24-2013 |
20130287681 | SOMATOSTATIN RECEPTOR-BASED CANCER THERAPY - Methods and composition for cell-based therapy as well as somatostatin receptor-based therapy are described. For example, in certain aspects methods for administering an anti-tumor therapy using a signaling defective somatostatin receptor mutant are described. Furthermore, the invention provides compositions and methods involve a somatostatin constitutively active somatostatin receptor mutant. | 10-31-2013 |
20130287682 | FUNCTIONALIZING IMPLANTABLE DEVICES WITH A POLY (DIOL CITRATE) POLYMER - The present invention is directed to a novel poly (diol citrates)-based coating for implantable devices. More specifically, the specification describes methods and compositions for making and using implantable devices coated with citric acid copolymers or citric acid copolymers impregnated with therapeutic compositions and/or cells. | 10-31-2013 |
20130295004 | IL-1 BINDING PROTEINS - The present invention describes IL-1β binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1β. Binding proteins of the invention have high affinity for IL-1β and neutralize IL-1β activity. A binding protein of the invention can be a full-length antibody or an IL-1β-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1β binding proteins of the invention are useful for detecting IL-1β and for inhibiting IL-1β activity, including in a human subject suffering from a disease or disorder in which IL-1β activity is detrimental. | 11-07-2013 |
20130295005 | Combination Therapy With Anti-CD74 Antibodies Provides Enhanced Toxicity to Malignancies, Autoimmune Disease and Other Diseases - Disclosed are compositions and methods comprising combinations of anti-CD74 antibodies with a therapeutic agent that is attached to the anti-CD74 antibody or separately administered. Preferably, the therapeutic agent is an antibody that binds to an antigen different from CD74, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80, IL-6, CXCR4 or HLA-DR. However, the therapeutic agent may be an immunomodulator, a cytokine, a toxin or other known therapeutic agent. Preferably, the anti-CD74 antibody is part of a DNL complex. More preferably, combination therapy with the anti-CD74 antibody and therapeutic agent is more effective than antibody alone, therapeutic agent alone, or the combination of unconjugated anti-CD74 antibody and therapeutic agent. Administration of combination induces apoptosis of target cells in diseases in which CD74 is overexpressed, such as solid tumors, B-cell lymphomas or leukemias, autoimmune disease, immune dysfunction disease or diabetes. | 11-07-2013 |
20130302242 | GENE SIGNATURES FOR CANCER DIAGNOSIS AND PROGNOSIS - Biomarkers and methods using the biomarkers for molecular detection and classification of disease and, particularly, molecular markers for cancer diagnosis and prognosis and methods of use thereof are provided. | 11-14-2013 |
20130309166 | Injection Molding of Poly-4-Hydroxybutyrate - Compositions of P4HB and processes to injection mold these compositions have been developed. These compositions are prepared from P4HB polymers and blends having intrinsic viscosities less than 3.2 dl/g but greater than 0.8 dl/g, moisture contents of less than 0.5% by weight, and more preferably less than 0.05% by weight, and using a polymer melt temperature during molding of at least 150° C. A preferred embodiment comprises a P4HB molding with an intrinsic viscosity of less than 3.2 dl/g that degrades rapidly in vivo. | 11-21-2013 |
20130336880 | METHODS FOR IN VIVO IDENTIFICATION OF CANCER INITIATING CELLS BY MULTIMODALITY REPORTER GENE IMAGING - The present invention relates to a method for detecting cancer initiating cells in living animal body by multimodality reporter gene imaging. In the method of this invention, cells escaping from cell loss during tumor enlargement are identified as cancer initiating cells. | 12-19-2013 |
20130336881 | METHOD AND DEVICE FOR ACCURATE DISPENSING OF RADIOACTIVITY - A method of delivering a radioactive liquid, includes, performing an initialization, including; extracting at least a first amount of a radioactive liquid from a source of radioactive liquid, measuring a radioactivity level for the first amount of radioactive liquid, and performing a calibration phase. The calibration phase includes, extracting a second amount of radioactive liquid from the source of radioactive liquid wherein the second amount is calculated based on the radioactivity level of the first amount to provide a total dose of radioactive liquid having a predetermined radioactivity level, and delivering the total dose and performing at least one more calibration and delivery phases. | 12-19-2013 |
20130336882 | ADHESIVE COMPOSITION FOR SOFT TISSUES, ADHESIVE COMPOSITION FOR WOUND DRESSING OR WOUND DRESSING COMPOSITION - The adhesive composition for soft tissues, the adhesive composition for wound dressing or the wound dressing agent composition of the present invention is an adhesive composition for soft tissues, an adhesive composition for wound dressing or a wound dressing agent composition, comprising a monomer (A), a polymer (B) and a polymerization initiator composition (C) containing an organoboron compound, and is characterized by having a viscosity of 0.4 to 75,000 cp within 30 seconds after mixing of the components (A), (B) and (C). The composition of the present invention not only has low toxicity, low harmfulness and high adhesive strength but also is excellent in workability during application and is capable of forming films of excellent properties. | 12-19-2013 |
20130336883 | DEOXYCYTIDINE KINASE BINDING COMPOUNDS - The invention provides compounds that bind to deoxycytidine kinase (dCK) and compositions including pharmaceutically acceptable compositions containing the compounds. The compounds are useful in treating diseases and disorders where dCK activity is implicated such as cancer and immune disorders. The compounds also find use in clinical methodologies including positron emission tomography (PET) imaging. | 12-19-2013 |
20130343987 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS - A myocardial imaging method that is accomplished by administering one or more adenosine A | 12-26-2013 |
20140023583 | METHOD OF MEASURING AND COMPARING LEVELS OF SUBSTANCES IN AN INDIVIDUAL'S BODY - A method for measuring the homeostatic relationship between various substances in the body. The measured levels of substances in the body use the interrelationships of the various substances in order to establish guidelines for treating individuals. | 01-23-2014 |
20140030186 | COMBINED PHARMACEUTICAL PREPARATION - The invention relates to a combined pharmaceutical composition or pharmaceutical preparation, comprising a first component containing a first ligand for a polyspecific lectin in a reticuloendothelial cell and a second component containing a carrier, a labeling agent, or a medicament for treating a disease associated with a target cell, each of which is targeted by a second ligand for a polyspecific lectin in a reticuloendothelial cell different from the first ligand, and also relates to a method for labeling a target cell and a method for treating a disease associated with a target cell, each using the same. | 01-30-2014 |
20140037538 | N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS - The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5′-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A | 02-06-2014 |
20140050660 | T-Cell Redirecting Bispecific Antibodies for Treatment of Disease - The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon-based agents that comprise interferon-α, interferon-β, interferon-λ1, interferon-λ2 or interferon-λ3. | 02-20-2014 |
20140056806 | Self-Assembling Biomimetic Hydrogels Having Bioadhesive Properties - The disclosure relates to a composition that is liquid at a temperature below the body temperature of a mammal and that solidifies at or above the body temperature of the mammal. The composition includes a thermally-desolubilizable polymer interspersed with a polymeric component of extracellular matrix and an encapsulated form of an amine compound (preferably an aminated component of extracellular matrix) that is de-encapsulated in the body of the mammal. The polymeric component is able to form covalent bonds with amine moieties in the aminated component, in one or more tissues in the body of the mammal, or both. Upon injection of a liquid suspension of these components into the body of the mammal, the thermally-desolubilizable polymer condenses, entrapping the polymeric component. The polymeric component binds covalently with a tissue in the body, and the aminated component end-caps the remaining reactive moieties of the polymeric component, forming a matrix at the site of injection. The disclosure also relates to uses of such compositions for forming a matrix on or within the body of a mammal. The compositions have a variety of uses, such as as bioadhesives, as sealants for ruptured tissues, as drug or imaging agent depots, or as mechanical cushions. | 02-27-2014 |
20140056807 | LARGE ONCOSOMES IN HUMAN TUMORS AND IN CIRCULATION IN PATIENTS WITH CANCER - The invention provides methods for isolating large oncosomes and determining cancer metastasis based on the presence of large oncosomes in a subject in need thereof. | 02-27-2014 |
20140065061 | CURCUMIN-ER, A LIPOSOMAL-PLGA SUSTAINED RELEASE NANOCURCUMIN FOR MINIMIZING QT PROLONGATION FOR CANCER THERAPY - The present invention includes compositions and methods of making a nanoparticle composition comprising a polymeric core comprising one or more polymers and one or more active agents, and at least one layer of one or more lipids on the surface of the polymeric core; more specifically, the invention relates to the use of curcumin within such a lipid-polymer nanoparticle formulation for minimizing QT prolongation associated with curcumin in treatment of cancer. | 03-06-2014 |
20140065062 | Halogenated Di and Trisaccharides, Pharmaceutical Formulations, Diagnostic Kits and Methods of Treatment - The present invention relates to a novel family of alkylated halogenated di- and trisaccharides which exhibit pharmaceutical efficacy in the areas of permeation enhancers, anti-microbial effects, anti-fugal effects, facilitation of diagnostic procedures. The invention further includes methods of treatment and diagnostic kits. | 03-06-2014 |
20140079628 | ANTI-TISSUE FACTOR ANTIBODIES AND COMPOSITIONS - Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer. | 03-20-2014 |
20140086825 | METHODS AND KITS FOR ASSESSING, MODULATING AND TREATING SUBSTANCES AFFECTING BODILY PROCESSES - Methods, systems, kits and devices for assessing and providing for homeostasis of signaling molecules in an individual via assessing, modulating and treating levels of modulators are provided. | 03-27-2014 |
20140086826 | SIN3B COMPLEX INHIBITION FOR PREVENTING HEMATOLOGIC CHEMOTHERAPY- AND RADIOTHERAPY-INDUCED CYTOTOXICITY - Methods for inactivating Sin3B and its associated activities to prevent, inhibit or attenuate hematopoietic stem cell exhaustion and chemotherapy- and radiotherapy-induced hematologic cytotoxicity are provided. | 03-27-2014 |
20140086827 | Serum S100B And Uses Thereof - The invention is directed to a method of assessing blood brain barrier permeability in an individual comprising selectively or specifically detecting a level of S 100BB homodimer in a sample of the individual, and comparing the level of S 100BB homodimer in the sample to a level of S 100B a control. The invention is also directed to methods of determining the effectiveness of a treatment for a neurological disorder wherein blood-brain barrier permeability is present in an individual in need thereof comprising detecting a level of S100B in a sample of the individual undergoing the treatment, and comparing the level of S 100B in the sample to the level of S100B in a sample from the individual obtained prior to treatment. The invention is also directed to a method of detecting a history of blood brain barrier disruption in an individual in need thereof comprising detecting auto | 03-27-2014 |
20140099254 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE - The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The leukocyte redirecting complexes have at least one binding site for a leukocyte antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other leukocyte antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cells associated with cancer or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC. | 04-10-2014 |
20140127126 | Compositions and Methods for Assessing and Treating Adrenal Diseases and Disorders - The present invention relates to the discovery that mutations in KCNJ5 are associated with adrenal diseases and disorders. The invention includes compositions and methods for the assessment, characterization and treatment of adrenal diseases and disorders, based upon the presence or absence of a KCNJ5 mutation that is associated with an adrenal disease or disorder. | 05-08-2014 |
20140127127 | HEPSIN INHIBITORS - Compositions and methods are provided for preventing or attenuating cancer progression or blocking metastasis in prostate cancer and other cancers (e.g., ovarian carcinoma, endometrial cancer, renal cell carcinoma) that are characterized by overexpression of the type II cell surface serine protease hepsin, based on the discovery of multiple disclosed compounds having activity as specific hepsin inhibitors. | 05-08-2014 |
20140134102 | Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies - The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis. | 05-15-2014 |
20140140922 | METHODS FOR TREATING CHRONIC KIDNEY DISEASE - The present invention relates to methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject. | 05-22-2014 |
20140161719 | PORPHYRIN MODIFIED TELODENDRIMERS - The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics. | 06-12-2014 |
20140161720 | TREATMENT OF ANGIOGENIC- OR VASCULAR-ASSOCIATED DISEASES - Described herein are methods and compositions comprising a compound of formula (I), e.g., dehydro-alpha-lapachone, or an analog, derivative, isomer, prodrug, or pharmaceutically acceptable salt thereof, for treatment and/or prevention of angiogenic- or vascular-associated diseases or disorders. The compound has anti-vascular activity. In some embodiments, the compound has anti-vascular activity that targets pathways other than VEGF pathways. In some embodiments, the compound or the composition further comprises anti-tumor activity. In some embodiments, the compound or the composition can decrease adhesion or motility of at least one cell (e.g., endothelial cells or cancer cells). | 06-12-2014 |
20140178293 | METHODS FOR IMAGING BONE PRECURSOR CELLS USING DUAL-LABELED IMAGING AGENTS TO DETECT MMP-9 POSITIVE CELLS - The present invention includes embodiments for methods and compositions that identify the presence of or risk for developing heterotopic ossification, particularly prior to mineralization of the bone. In particular embodiments, MMP-9 and/or MMP-2 agents comprising dual imaging moieties are used to identify patterns of MMP-9 and/or MMP-2 localization, respectively, that is then predictive of heterotopic ossification. | 06-26-2014 |
20140178294 | Ultrafiltration Concentration of Allotype Selected Antibodies for Small-Volume Administration - Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies. | 06-26-2014 |
20140178295 | Method for Treating Psoriasis By Administering An Anti-IL-12 Antibody - Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis. | 06-26-2014 |
20140193329 | ANTI-CD151 ANTIBODIES AND THEIR USE IN THE TREATMENT OF CANCER - The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers. | 07-10-2014 |
20140199232 | Targeted Therapeutic Nanoparticles - Disclosure of methods and compositions related to chemical conjugations to nanoparticles of polysaccharides cross-linked to poloxamers as well as nano-sized colloids comprised of polysaccharides and poloxamers. The nanoparticles may be produced by various methods including inverse miniemulsion polymerization processes which create nanogels of desired size, shape, and stability for controlled therapeutic drug delivery, imaging, and theragnostic applications. | 07-17-2014 |
20140199233 | Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor - The present invention relates to the fabrication and uses of liposomal nanoparticles. | 07-17-2014 |
20140199234 | BCL-2/BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME - Inhibitors of Bcl-2/Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2/Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2/Bcl-xL provides a benefit, like cancers, also are disclosed. | 07-17-2014 |
20140219912 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 08-07-2014 |
20140219913 | Dual Specific Binding Proteins Having a Receptor Sequence - Engineered multispecific binding proteins that bind at least one ligand for a receptor are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 08-07-2014 |
20140234208 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 08-21-2014 |
20140234209 | CHIMERIC AND HUMANIZED ANTI-HISTONE ANTIBODIES - The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g., SLE), atherosclerosis, arthritis, rheumatoid arthritis, edema, sepsis, septic shock, hyperinflammatory disorder, infectious disease, inflammatory disease, immune dysregulatory disorder, GVHD, transplant rejection, atherosclerosis, asthma, a coagulopathy, myocardial ischemia, thrombosis, nephritis, inflammatory liver injury, acute pancreatitis, ischemia-reperfusion injury, stroke, cardiovascular disease, and burn. | 08-21-2014 |
20140241983 | Methods and Compositions for Enhancing the Therapeutic Effect of Anti-Tumor T Cells - Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor. | 08-28-2014 |
20140248209 | ANTI-TUMORAL COMPOUND AND RELATIVE PRODUCTION PROCESS - An anti-tumoral compound for the localized treatment of neoplastic pathologies of malignant kind that cannot be surgically removed or with a high risk of local recurrence, includes: a bicomponent injectable biologic glue; an antineoplastic substance; and an epinephrine-based solution. The compound may be used as an independent therapeutic treatment, as it allows to treat tumoral masses that are not surgically removable, or as a therapeutic treatment complementary to surgical removal or to known ablative techniques (laser, radiofrequency, microwaves, etc.) for a maximization of the efficiency of therapies reducing the risk of neoplastic relapses in the original surgical site. A process for the production of the antitumor compound is also described. | 09-04-2014 |
20140255298 | RADIOPAQUE MARKERS FOR IMPLANTABLE MEDICAL LEADS - A radiopaque marker may include a body formed of a polymer and being adapted to be disposed around a portion of an implantable medical lead and a symbol formed of at least a radiologically dense powder or liquid added to the body and designed to identify the implantable medical lead as being safe application of a medical procedure. In some instances, the symbol may be formed of a polymer mixed with the radiologically dense powder or liquid. The body may also be formed of a polymer mixed with a radiologically dense powder or liquid wherein the mixed polymer forming the symbol is radiologically denser than the mixed polymer forming the body. | 09-11-2014 |
20140255299 | Methods and Compositions Comprising a C-Terminal Bax Peptide - In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells. | 09-11-2014 |
20140255300 | FAP-Activated Proteasome Inhibitors for Treating Solid Tumors - Disclosed are proteasome inhibitors, fibroblast activation protein (FAP)-activated prodrugs of proteasome inhibitors, and pharmaceutically acceptable salts of the inhibitors and prodrugs. Also disclosed are related pharmaceutical compositions, and methods of using the inhibitors and prodrugs and compositions thereof, for example, in treating cancer or other cell proliferative diseases. In vitro and in vivo methods of quantifying the expression of FAP in a biopsy sample and a mammal, respectively, are also disclosed. | 09-11-2014 |
20140271453 | METHODS FOR THE EARLY DETECTION OF LUNG CANCER - Provided are methods of diagnosing lung cancer, particularly at an early stage, such as stage I, by detecting the presence and/or amount of at least four biomarkers of lung cancer in a sample from a subject as well as determining the number of smoking pack years for the subject. The methods and biomarkers may be used to develop an accurate prognosis for a patient having lung cancer or suspected of having lung cancer or accurately diagnose a subject having or suspected of having lung cancer. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for lung cancer treatment therapy. | 09-18-2014 |
20140271454 | CELL-SYNTHESIZED PARTICLES - The present technology provides for a cell-synthesized biological particle, the processes for making a cell-synthesized particle, and a process for assembling such cell-synthesized particles into tissues and organs. The particles are synthesized in culture in vitro by living cells that produce natural extracellular matrix. Multiple particles can be assembled into tissues that have significant void space. The particles or tissues can act as a substrate for additional cell types. The particles or tissues can be further cultured in vitro to achieve favorable cell or extracellular matrix growth, organization or other desired characteristics. The particles or tissues can be devitalized or decellularized. The particles or tissues can be injected or implanted in a human to repair, enhance, or create a secretory, mechanical, or aesthetic function. | 09-18-2014 |
20140271455 | DNA METHYLATION BIOMARKERS FOR SMALL CELL LUNG CANCER - The methods provided herein relate to the identification of novel DNA biomarkers and the use of the aberrant methylation patterns of the DNA biomarkers to diagnose small cell lung cancer (SCLC). Such methods may include diagnosing SCLC when there is an increase in methylation of one or more DNA biomarkers in a test sample compared with that in a normal sample. DNA methylation patterns of DNA biomarkers on a genome-wide scale may be determined using a variety of methods including the methylated-CpG island recovery assay (MIRA). In some embodiments, methods of treating a subject for SCLC or monitoring the treatment are also provided. Methods may include measuring the methylation levels of one or a combination of DNA biomarkers and administering chemotherapy to a subject when there is an increase in the methylation levels of the test sample in relation to that of the normal sample or standard sample. | 09-18-2014 |
20140271456 | RADIOTRACER IMAGING USING SODIUM IODIDE SYMPORTER POLYPEPTIDES - This document provides methods and materials involved in radiotracer imaging using NIS polypeptides. For example, methods and materials for performing imaging techniques that increase the detection sensitivity and resolution of radiotracers localized by NIS reporter gene expression and/or decrease background signals that can be attributed to endogenously expressed NIS polypeptides are provided. | 09-18-2014 |
20140271457 | Dual Specific Binding Proteins Directed Against TNF - Engineered multivalent and multispecific binding proteins that bind TNFα and IL-13, TNFα and PGE2, or TNFα and NGF are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 09-18-2014 |
20140271458 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17 - Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 09-18-2014 |
20140271459 | ANTIBODIES TO HGF AND COMPOSITIONS CONTAINING - The present invention is directed to antibodies and fragments thereof having binding specificity for HGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 09-18-2014 |
20140271460 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents - This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders. | 09-18-2014 |
20140301943 | INDUCTION OF THYROID IODIDE-HANDLING GENE EXPRESSION IN HUMAN CANCERS - Dual suppression of the MAP kinase and PI3K/Akt pathways showed synergistic or greatly enhanced anti-melanoma cell effects, compared to suppression of a single pathway, including the inhibition of cell proliferation, transformation and invasion, induction of G | 10-09-2014 |
20140301944 | LOW MOLECULAR WEIGHT THYROID STIMULATING HORMONE RECEPTOR (TSHR) AGONISTS - Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder. | 10-09-2014 |
20140314661 | Diagnostic System for the Detection of Skin Cancer - Methods and compositions are provided for the analysis of skin surfaces to determine the presence of neoplastic tissue. In the methods of the invention, a composition comprising a florescent probe that binds to a specific neoplasia associated marker is applied topically to the area of interest. After topical administration, the probe preferentially binds to markers associated in neoplastic lesions in situ, which binding is detected with a compact illumination unit that provides illumination at a wavelength appropriate for image acquisition. The illumination unit comprises a light source and fiber optic bundle to direct the light towards the area of examination. A detection unit is used to capture and record an image of the area of investigation. The detection unit may be a digital camera, film camera, etc. A mapping module may also be provided to catalogue the site of examination. | 10-23-2014 |
20140314662 | METHODS AND KITS FOR THE PROGNOSIS OF COLORECTAL CANCER - The invention relates to methods for predicting the risk of relapse of cancer patients as well as methods for providing personalized medicine to said patients based on the expression levels of different genes the expression of which is induced in response to TGF-beta stimulation. The invention also relates to kits for carrying out the diagnostic and predictive medicine methods. | 10-23-2014 |
20140314663 | PEPTIDE-MEDIATED DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER - Provided herein are methods for transporting an active agent (e.g., a therapeutic agent or an imaging agent) across the blood-brain barrier (BBB) in a patient. For example, the methods provided herein can be used to treat a brain disease in a patient, such as brain cancer. In some embodiments, the methods provided herein can be used to image the central nervous system of a patient. | 10-23-2014 |
20140322128 | Materials and Methods Useful to Induce Cell Death via Methuosis - The present invention provides materials and methods to induce cell death by methuosis, a non-apoptotic cell death mechanism. Small molecules herein are useful for treating cell proliferation disorders or anomalies, particularly, but not exclusively, cancer. Methods related to the research and pharmaceutical use of the small molecules are also provided herein. | 10-30-2014 |
20140328750 | Antibodies Reactive with B7-H3 and Uses Thereof - The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers. | 11-06-2014 |
20140335014 | IL-1 ALPHA DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 11-13-2014 |
20140341801 | INACTIVATION OF SMOOTH MUSCLE TISSUE - Treatment and procedures for treating bodily conduits involves deactivating, killing, or otherwise treating smooth muscle tissue of the conduit. | 11-20-2014 |
20140356281 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17 - Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 12-04-2014 |
20140377168 | PHARMACEUTICAL GELS AND METHODS FOR DELIVERING THERAPEUTIC AGENTS TO A SITE BENEATH THE SKIN - Pharmaceutical gels and methods for delivering a therapeutic agent to a target tissue site beneath the skin of a patient are provided, the gel being capable of adhering to the target tissue site and comprising one or more biodegradable depots containing an effective amount of the therapeutic agent. In various embodiments, the gel is sprayable and hardens after contacting the target tissue site. | 12-25-2014 |
20150010469 | BISPHENOL ETHER COMPOUNDS WITH NOVEL BRIDGING GROUPS AND METHODS FOR THEIR USE - Compounds having a structure of Formula I: | 01-08-2015 |
20150017091 | DETECTION AND TREATMENT OF METASTATIC DISEASE - The establishment and growth of metastatic tumors can be detected and inhibited by the methods and compositions described herein. As illustrated herein, agents that inhibit the expression or activity of versican, for example, in bone marrow cells effectively halt the growth and establishment of metastatic tumors at distal sites from a primary tumor site. In general, the primary tumor is unaffected by versican inhibitors but metastasis is substantially eliminated. | 01-15-2015 |
20150017092 | DEVICES AND METHODS FOR DETERMINING SENSITIVITY TO RADIATION - Systems and methods for determining the sensitivity of cells (and/or a subject) to ionizing radiation are provided. The systems can comprise a microfluidic device comprising a plurality of microfluidic cavities each configured to contain cells; a source of ionizing radiation configured to deliver ionizing radiation to cells in the microfluidic cavities; and an imaging system configured to detect radiation-induced foci in cells when they are disposed in the microfluidic cavities. The methods can involve contacting a biological sample comprising cells from a subject with ionizing radiation; detecting and quantifying radiation induced foci in the cells at least two different time points; and determining a repair kinetic for radiation induced foci that is a measure of the rate of disappearance of the foci. Methodologies are also provided for in-home blood collection and fixation of nucleated blood cells in a manner to preserve health and fitness biomarkers inherent to these cells. | 01-15-2015 |
20150023867 | METHODS OF MYOCARDIAL PERFUSION IMAGING - The present invention provides a method of myocardial perfusion imaging using reduced doses of (1-{9-[(4S,2R,3R,5R)3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide. | 01-22-2015 |
20150023868 | HIF INHIBITORS AND USE THEREOF - The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders. | 01-22-2015 |
20150037248 | IL-1beta NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES - The present invention is directed to antigen binding proteins and in particular to IL-1β antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production. | 02-05-2015 |
20150037249 | USES OF POROUS NANOSTRUCTURE IN DELIVERY - The present invention relates to methods for delivering at least one agent unto or into a biological sample or a biological subject. The methods comprise a step of contacting the biological sample or subject with a payload-carrying nanostructure. The nanostructure can be a porous low density nanostructure. | 02-05-2015 |
20150044134 | COMPOSITIONS, METHODS AND KITS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES - The present invention is directed to fusion proteins having an IL-21 cytokine portion and an anti-CD20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the IL-21-anti-CD20 fusion proteins. In particular, the methods, kits and compositions of the invention are useful in the treatment of cancer and autoimmune diseases. | 02-12-2015 |
20150056131 | THERMOFORMED POLY-4-HYDROXYBUTYRATE MEDICAL IMPLANTS - Methods to produce thermoforms from P4HB homopolymer and blends thereof have been developed. These thermoforms are produced from films and sheets including P4HB, wherein the intrinsic viscosity of the P4HB is less than 3.5 dl/g, but greater than 0.35 dl/g, and the thermoforms are produced at a temperature equal to or greater than the softening point of P4HB, and more preferably at a temperature higher than the melting point of P4HB. A preferred embodiment includes a P4HB thermoform wherein a film or sheet including a P4HB polymer is thermoformed at a temperature between its melting point and 150° C. In a particularly preferred embodiment the thermoform is a laminate made from a P4HB film and a P4HB mesh. | 02-26-2015 |
20150064106 | Biodegradable Polyphosphazenes Containing Pyrrolidone Side Groups - Biodegradable polyphosphazene polymers containing pyrrolidone side groups, and the biomedical use of such polyphosphazene polymers are disclosed. | 03-05-2015 |
20150086476 | SYSTEMS, METHODS AND APPARATUS FOR MANUFACTURING RADIOISOTOPES - A standalone radiopharmaceutical preparation hotcell for preparing a radiopharmaceutical includes a housing and a plurality of compartments defined within the housing. The plurality of compartments including at least a pharmaceutical synthesizing and dispensing compartment and a different second compartment, the synthesizing and dispensing compartment being maintained at a first pressure and the second compartment being maintained at a different second pressure using a compartment pressurization system. | 03-26-2015 |
20150086477 | HIGHLY SENSITIVE SURVEILLANCE USING DETECTION OF CELL FREE DNA - Provided herein are methods and computer-readable storage media related to cell-free DNA and uses thereof to determine risk of a condition, such as transplant rejection or cancer, in a subject. | 03-26-2015 |
20150098894 | SET AND METHOD FOR THE PRODUCTION OF A RADIOPHARMACEUTICAL - A set for producing a radiopharmaceutical, having a cation exchange cartridge; a reaction vial containing a precursor marker; a solution vial containing a solvent; an elution vial containing a sterile solution that includes sodium chloride (NaCl) and hydrochloric acid (HCl); a buffer salt. A method for producing a radiopharmaceutical is also disclosed. | 04-09-2015 |
20150098895 | SET AND METHOD FOR THE PRODUCTION OF A RADIOPHARMACEUTICAL - A set for producing a radiopharmaceutical, having a cation exchange cartridge; a reaction vial containing a precursor marker; a solution vial containing a solvent; an elution vial containing a sterile solution that includes sodium chloride (NaCl) and hydrochloric acid (HCl); a buffer salt. A method for producing a radiopharmaceutical is also disclosed. | 04-09-2015 |
20150098896 | SET AND METHOD FOR THE PRODUCTION OF A RADIOPHARMACEUTICAL - A set for producing a radiopharmaceutical, having: a cation exchange cartridge; a reaction vial containing a precursor marker; a solution vial containing a solvent; an elution vial containing a sterile solution that includes sodium chloride (NaCl) and hydrochloric acid (HCl); a buffer salt. A method for producing a radiopharmaceutical is also disclosed. | 04-09-2015 |
20150118152 | PULTRUSION OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF - Compositions of P4HB (poly-4-hydroxybutyrate) and copolymers thereof, have been developed for pultrusion, as well as processes to produce profiles from these compositions by pultrusion. These pultrusion processes provide profiles without causing structural damage to the surface of the profile. The profiles may be used in medical applications. These compositions include P4HB, and copolymers thereof, having intrinsic viscosities less than 3.2 dl/g but greater than 0.8 dl/g. The profile may be formed using conditions such as: pull rate of 0.1 to 100 mm/min, die temperature of up to 95° C., rod stock temperature up to 95° C., draw ratio of up to 100×, pulling force of greater than 10 MPa, and clamping pressure at least 10% higher than the pulling force. Preferably, the profile is formed by pulling the rod stock through a series of dies placed at intervals with the hole sizes decreasing in diameter by 0.1 to 10 mm. | 04-30-2015 |
20150125384 | MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES - Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and subtraction of antigen, adjuvant, immune potentiators, molecular recognition and transport mediation elements, as well as intracellular uptake mediators, allows for exquisite control over variables that are important in optimizing an effective vaccine delivery system. | 05-07-2015 |
20150132217 | DISEASE THERAPY BY INDUCING IMMUNE RESPONSE TO TROP-2 EXPRESSING CELLS - The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2 | 05-14-2015 |
20150147270 | CONSTRUCTS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASES AND COLON CANCER - The present invention features, inter alia, constructs for the delivery of therapeutic and diagnostic agents to a patient. The constructs can include a nanoparticle, a targeting agent that specifically binds a targeted tissue or cell, a therapeutic moiety, and a hydrogel. The constructs can be used in the treatment and diagnosis of bowel diseases, including inflammatory bowel disease (IBD) and colon cancer. In one embodiment, the therapeutic agent is a nucleic acid that mediates RNA inhibition (RNAi), and the invention is directed to treatments for IBD that combine the positive aspects of such agents {e.g., siRNAs) with the safety of a biodegradable polymeric delivery system to facilitate specific targeting of colonic tissues and cells. As the constructs can be formulated for oral administration, they are well tolerated and offer advantages with regard to patient compliance. | 05-28-2015 |
20150306244 | Anthracycline-Antibody Conjugates for Cancer Therapy - The invention relates to therapeutic conjugates with the ability to target various antigens. The conjugates contain a targeting antibody or antigen binding fragment thereof and an anthracycline chemotherapeutic drug. The targeting antibody and the chemotherapeutic drug are linked via a linker comprising a hydrazide moiety. | 10-29-2015 |
20150306257 | PHARMACEUTICAL PREPARATION - A pharmaceutical preparation comprising at least one complexed alpha-emitting radionuclide and at least one polysaccharide biopolymer. | 10-29-2015 |
20150315290 | MULTISPECIFIC ANTIBODIES - The invention provides multispecific antibodies and methods of making and using such antibodies. | 11-05-2015 |
20150320682 | NANOPARTICULATE MEGESTROL FORMULATIONS - The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about | 11-12-2015 |
20150335749 | CHAIN-EXTENDING POLOXAMERS, THERMOREVERSIBLE HYDROGELS FORMED BY THEM WHICH INCLUDE BIOLOGICAL MATERIALS, AND MEDICINAL APPLICATIONS OF SAME - According to the invention, thermoreversible hydrogels are provided, which are prepared from chain-extended poloxamers, having advantageous properties. In addition, the invention provides thermoreversible hydrogels, including biological materials, and a process for the preparation thereof, thermoreversible hydrogels including living cells, application systems for pharmaceutical applications, and an in-vitro-method for forming a composition on a surface. | 11-26-2015 |
20160000915 | CROSSLINKING OF CD22 BY EPRATUZUMAB TRIGGERS BCR SIGNALING AND CASPASE-DEPENDENT APOPTOSIS IN HEMATOPOIETIC CANCER CELLS - Extensive crosslinking of CD22 by plate-immobilized epratuzumab induced intracellular changes in Daudi cells similar to ligating B-cell antigen receptor (BCR) with a sufficiently high amount of anti-IgM. Either treatment leads to phosphorylation of CD22, CD79a and CD79b, along with their translocation to lipid rafts, both of which were needed to induce caspase-dependent apoptosis. Immobilization also induced stabilization of F-actin, phosphorylation of Lyn, ERKs and JNKs, generation of reactive oxygen species (ROS), decrease in mitochondria membrane potential (Δψ | 01-07-2016 |
20160002343 | BLOOD-BRAIN BARRIER (BBB) PENETRATING DUAL SPECIFIC BINDING PROTEINS FOR TREATING BRAIN AND NEUROLOGICAL DISEASES - Engineered agents or multivalent and multispecific binding proteins capable of penetrating the cells or tissue of the blood-brain barrier (BBB) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 01-07-2016 |
20160011211 | METHODS TO PREDICT AND PREVENT RESISTANCE TO TAXOID COMPOUNDS | 01-14-2016 |
20160024023 | LOW MOLECULAR WEIGHT THYROID STIMULATING HORMONE RECEPTOR (TSHR) AGONISTS - Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder. | 01-28-2016 |
20160024503 | miRNA BIOGENESIS IN EXOSOMES FOR DIAGNOSIS AND THERAPY - Methods for diagnosis and treatment of cancers by use of exosomes comprising miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes. | 01-28-2016 |
20160031986 | Therapeutic DLL4 Binding Proteins - DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis. | 02-04-2016 |
20160038407 | FLOWABLE COMPOSITION THAT HARDENS ON DELIVERY TO A TARGET TISSUE SITE BENEATH THE SKIN - Flowable compositions and methods are provided for delivering a therapeutic agent at or near a target tissue site beneath the skin of a patient, the flowable composition comprising (i) a solvent and (ii) an effective amount of the therapeutic agent, the flowable composition being capable of hardening to form a drug depot at a physiological temperature or as solvent contacts bodily fluid at or near the target tissue site, wherein the drug depot is capable of releasing the therapeutic agent over a period of at least one day and the target tissue site comprises at least one muscle, ligament, tendon, cartilage, spinal disc, spinal foraminal space near the spinal nerve root, facet or synovial joint, or spinal canal. In some embodiments, an implantable drug depot for delivering a therapeutic agent is provided, the implantable drug depot comprising (i) a chamber; and (ii) a flowable composition comprising an effective amount of a therapeutic agent disposed within the chamber of the drug depot, the flowable composition capable of hardening when the drug depot is delivered at or near the target tissue site. | 02-11-2016 |
20160038418 | NANOPARTICLE FABRICATION METHODS, SYSTEMS, AND MATERIALS - Nano-particles are molded in nano-scale molds fabricated from non-wetting, low surface energy polymeric materials. The nano-particles can include pharmaceutical compositions, taggants, contrast agents, biologic drugs, drug compositions, organic materials, and the like. The molds can be virtually any shape and less than 10 micron in cross-sectional diameter. | 02-11-2016 |
20160040250 | TERT PROMOTER MUTATIONS IN CANCER - The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions related to certain promoter mutations in cancer. In one embodiment, a method for treating a subject having thyroid cancer comprises the steps of (a) obtaining a biological sample from the subject; (b) performing an assay on the sample obtained from the subject to identify a mutation at 1 295 228 C>T (C228T) and 1 295 250 C>T (C250T), corresponding to −124 C>T and −146 C>T from the translation start site in the promoter of the telomerase reverse transcriptase (TERT) gene; (c) identifying the subject as having or likely to develop aggressive thyroid cancer if the C228T and/or C250T mutation is identified; and (d) treating the subject with one or more treatment modalities appropriate for a subject having or likely to develop aggressive thyroid cancer. | 02-11-2016 |
20160046680 | RADIOTRACER IMAGING USING SODIUM IODIDE SYMPORTER POLYPEPTIDES - This document provides methods and materials involved in radiotracer imaging using NIS polypeptides. For example, methods and materials for performing imaging techniques that increase the detection sensitivity and resolution of radiotracers localized by NIS reporter gene expression and/or decrease background signals that can be attributed to endogenously expressed NIS polypeptides are provided. | 02-18-2016 |
20160058905 | RADIOACTIVE BONE CEMENT - A target tissue can be treated with a radioisotope. Some methods for treating a target tissue with a radioisotope include determining a distance between a target tissue and a surface of a matrix material to be positioned adjacent the target tissue and, based on the determined distance, determining an activity to be mixed with the matrix material to obtain a desired activity concentration. Some methods further include mixing the radioisotope with the matrix material. In some embodiments, the matrix material comprises bone cement, and the target tissue is a tumor in a bone. The radioisotope may be a beta-emitting radioisotope mixed in the cement at a concentration to form a radioactive cement. | 03-03-2016 |
20160067257 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY - The present invention embraces methods for identifying compounds that modulate the activity of telomerase. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the TRBD, “thumb,” “finger,” and/or “palm” domain; or FP-pocket, PT-pocket or Th-pocket of telomerase and testing the compound for its ability to modulate the activity of telomerase. Compounds selected for interacting with the T-pocket or Fingers-Palm pocket of telomerase are also provided. | 03-10-2016 |
20160068466 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE - Compounds having a structure of Structure I: | 03-10-2016 |
20160083469 | TARGETING CONSTRUCTS BASED ON NATURAL ANTIBODIES AND USES THEREOF - The present invention provides targeted delivery methods and constructs for treating inflammatory diseases and/or detecting in vivo tissue injuries in an individual. The targeted delivery approach utilizes an antibody that recognises an epitope found to be present at sites of inflammation. The invention also provides methods of inhibiting complement-driven inflammation in the eye in an individual, comprising administering to the individual an antibody or a fragment thereof or compositions thereof, wherein the antibody or fragment thereof specifically binds to Annexin IV or phospholipid. Also provided are related methods of treating a complement-associated ocular disease or an ocular disease involving oxidative damage. Additionally, the invention provides methods of detecting complement-mediated injury in an eye tissue of an individual, comprising administering to the individual a construct or compositions thereof, wherein the construct comprises (a) an antibody or fragment thereof that specifically binds to Annexin IV or phospholipid; and (b) a detectable moiety. | 03-24-2016 |
20160089454 | GEL FORMULATIONS FOR GUIDING RADIOTHERAPY - The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body. | 03-31-2016 |
20160090414 | BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF - Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. | 03-31-2016 |
20160101128 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS - The invention provides methods of inducing an immune response to cancer comprising co-administering to a cancer patient one or more TLR9 agonists and one or more checkpoint inhibitors. Preferably, the one or more TLR9 agonists are administered to the patient via intratumoral (i.t.) administration. | 04-14-2016 |
20160106852 | TARGETED THERAPEUTIC NANOPARTICLES - Disclosure of methods and compositions related to chemical conjugations to nanoparticles of polysaccharides cross-linked to poloxamers as well as nano-sized colloids comprised of polysaccharides and poloxamers. The nanoparticles may be produced by various methods including inverse miniemulsion polymerization processes which create nanogels of desired size, shape, and stability for controlled therapeutic drug delivery, imaging, and theragnostic applications. | 04-21-2016 |
20160106866 | TRIPARTITE CANCER THERANOSTIC NUCLEIC ACID CONSTRUCTS - The presently disclosed subject matter generally relates to genetic constructs and methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. In particular, the presently disclosed subject matter relates to tripartite cancer theranostic nucleic acid constructs that permit simultaneous cancer specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene. | 04-21-2016 |
20160130333 | Chimeric and Humanized Anti-Histone Antibodies - The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g., SLE), atherosclerosis, arthritis, rheumatoid arthritis, edema, sepsis, septic shock, hyperinflammatory disorder, infectious disease, inflammatory disease, immune dysregulatory disorder, GVHD, transplant rejection, atherosclerosis, asthma, a coagulopathy, myocardial ischemia, thrombosis, nephritis, inflammatory liver injury, acute pancreatitis, ischemia-reperfusion injury, stroke, cardiovascular disease, and burn. | 05-12-2016 |
20160146820 | Method for the Prognosis of Survival Time of a Patient Suffering from a Solid Cancer - The present invention relates to an in vitro method for the prognosis of survival of a patient suffering from a solid cancer, comprising the quantification of the cell density of CD8+ cells and DC-LAMP+ dendritic cells present in a tumor tissue sample from said patient, wherein a high density of CD8+ cells and DC-LAMP+ dendritic cells indicates that the patient has a favorable prognosis, a high density of CD8+ cells and a low density of DC-LAMP+ dendritic cells indicates that the patient has a poor prognosis, and a low density of CD8+ cells and DC-LAMP+ dendritic cells indicates that the patient has the worst prognosis. | 05-26-2016 |
20160166714 | CYCLIC PEPTIDES WITH ENHANCED NERVE-BINDING SELECTIVELY, NANOPARTICLES BOUND WITH SAID CYCLIC PEPTIDES, AND USE OF SAME FOR REAL-TIME IN VIVO NERVE TISSUE IMAGING | 06-16-2016 |
20160166727 | Methods of Orienting Multifilament Yarn and Monofilaments of Poly-4-Hydroxybutyrate and Copolymers Thereof | 06-16-2016 |
20160184415 | COMPOSITIONS FOR AND METHODS OF TREATING AND PREVENTING TARGETING TUMOR ASSOCIATED CARBOHYDRATE ANTIGENS - Compositions useful to induce anti-TACA immune response and kits comprising the same and methods of using the compositions to treat and prevent cancer are disclosed. Isolated human antibodies which bind to a carbohydrate mimetic peptide and methods of making the same and using the same to treat and prevent cancer are disclosed. Isolated human NK cells useful to kill tumor cells, and isolated human dendritic cells, and methods of making the same and using the same to treat and prevent cancer are disclosed. | 06-30-2016 |
20160193349 | FUCOIDAN NANOGELS AND METHODS OF THEIR USE AND MANUFACTURE | 07-07-2016 |
20160194405 | ANTI-TISSUE FACTOR ANTIBODIES AND COMPOSITIONS | 07-07-2016 |
20160199661 | CANCER CELL MEMBRANE DEPOLARIZATION | 07-14-2016 |
20170231986 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | 08-17-2017 |
20170233463 | Anti-Alpha Synuclein Binding Molecules | 08-17-2017 |
20190142939 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE | 05-16-2019 |
20190144535 | IL-1BETA NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES | 05-16-2019 |